

AUTHOR INDEX

Aaron, Jean E. See Fernández-Conde, Manuel

Abbruzese, J. L. See Pazdur, R.

Abdel-Wahab, May M. R.

—Wolfson, Aaron H.; Raub, William; Landy, Howard; Feun, Lynn; Sridhar, Kasi; Brandon, Alfred H.; Mahmood, Saleem; Markoe, Arnold M.: The role of hyperfractionated re-irradiation in metastatic brain disease: A single institutional trial, 158

Abella, E. See Varterasian, M.

Achard, Jean-Louis See Ferrière, Jean-Pierre

Adamietz, I. A. See Mose, S.

Adamietz, Ireneus A. See Mose, Stephan

Adams, P. T. See Varterasian, M.

Adelstein, David J. See Tan, Eng-Huat

Advani, S. H. See Kulkarni, S. S.

Ajani, J. See Pazdur, R.

Akutsu, Miyuki See Yokoi, Kohei

Albin, N. See Bachaud, J. M.

Alecover, Juan See Fernández-Conde, Manuel

Al-Katib, A. See Varterasian, M.

Aloe, A. See Nardi, M.

Amista, Pietro See Brandes, Alba Ariela

Anderson, Tom See Chitambar, Christopher R.

Andras, Ellis J. See Komaki, Ritsuko

Andrews, David W. See Glass, Jon

Antoine, Eric-Charles

—Rixe, Olivier; Auclerc, Gérard; Weil, Marise; Khayat, David; Docetaxel: A review of its role in breast cancer treatment, 429

Apostoli, Pietro See Micheletti, Enrico

Aramendia, Jose M. See Aristu, Javier

Arase, Yasuji See Ikeda, Kenji

Ardavanis, Alekos See Kosma, Lambrini

Aristu, Javier

—Rebolledo, José; Martínez-Monge, Rafael; Aramendia, Jose M.; Viera, Juan C.; Azinovic, Ignacio; Herreros, Jesús; Brugarolas, Antonio: Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: Final results of a phase II study, 276

Armstead, Barbara See Vaughn, David J.

Aron, Bernard S. See Barrett, William L.

Asbell, Sucho O. See Komaki, Ritsuko

Asbury, Robert

—Blessing, John A.; Look, Katherine Y.; Buller, Richard; Lucci, Joseph A., III: A phase II trial of amonafide in patients with nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, 626

Athanassiou, A. See Pectasides, D.

Atlante, G. See Nardi, M.

Auclerc, Gérard See Antoine, Eric-Charles

Axelrod, Rita See Glass, Jon

Azinovic, Ignacio See Aristu, Javier

Bachaud, J. M.

—Chatelut, E.; Canal, P.; Albin, N.; Yardeni, E.; David, J. M.; Serrano, E.; Daly-Schweitzer, N.: Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: Results of a phase I study, 1

Baert, Luc See Goethuys, Hans

Baert, Luc See Petrovich, Zbigniew

Bagshaw, Malcolm A. See Petrovich, Zbigniew

Baldini, Editta

—Tibaldi, Carmelo; Lencioni, Monica; Giannessi, Piergiorgio; Evangelista, Giuseppe; Roncella, Manuela; Spinelli, Claudio; Meucci, Claudio; da Prato, Miria; Conte, Pierfranco: Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients, 169

Ballesterro, Alberto

—Ferrando, Fabio; Stura, Paola; Puglisi, Maria; Brema, Fulvio; Patrone, Franco: Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP), 266

Barbanti, Ilaro See Cascinu, Stefano

Barrett, William L.

—Gluckman, Jack L.; Aron, Bernard S.: Safety of radiating jejunal interposition grafts in head and neck cancer, 609

Bastin, Kenneth T.

—Steeves, Richard A.; Richards, Marcia J. S.: Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: Case reports and literature review, 55

Basurto, Carlo See Colozza, Mariantonietta

Begbie, Stephen D.

—Bell, David R.; Nevell, David F.: Mediastinal epithelioid hemangiopericytoma in a patient with type IV Ehlers-Danlos syndrome: A case report and review of the literature, 412

Bekrada, Mohammed See Culine, Stéphane

Bélembaogo, Ernest See Ferrière, Jean-Pierre

Bell, David R. See Begbie, Stephen D.

Bellini, Andrew See Warner, Ellen

Belsanti, Virginio See Colozza, Mariantonietta

Benhammouda, A. See Rixe, O.

Ben-Yosef, Rami

—Or, Reuven; Naparstek, Ella; Kapelushnik, Joseph; Samuels, Simcha; Slavin, Shimon; Nagler, Arnon: Should soybean agglutinin purging be performed in breast cancer patients undergoing autologous stem cell transplantation? A retrospective analysis of 48 patients, 419

Bernhard, Michael See Mose, Stephan

Bernhart, Bernard See Rafi, Shahin

Beroukas, Kostantinos See Kosma, Lambrini

Berry, John See Ezzat, Adnan A.

Berti, Franco See Brandes, Alba Ariela

Bescos, Socorro See del Campo, Jose M.

Bianchi, Ernestina See Micheletti, Enrico

Bishop, J. F. See Michael, M.

Bishop, James F. See Parnis, Francis X.

Blake, Debbie S. See Jamis-Dow, Carlos A.

Blessing, John A. See Asbury, Robert

Blessing, John A. See Lincoln, Sarah

Blevins, Judith C. See Hong, Jack J.

Blijham, Geert H. See Hupperets, Pierre S.

Blitzer, Peter H. See Rubenstein, James H.

Bodi, Ramon See Felip, Enriqueta

Boisvert, D. See Maroun, J. A.

Borel, C. See Rixe, O.

Böttcher, Heinz D. See Mose, Stephan

Brady, Luther W. See Goethuys, Hans

Brady, Luther W. See Petrovich, Zbigniew

AUTHOR INDEX

Aaron, Jean E. See Fernández-Conde, Manuel

Abbruzese, J. L. See Pazdur, R.

Abdel-Wahab, May M. R.

—Wolfson, Aaron H.; Raub, William; Landy, Howard; Feun, Lynn; Sridhar, Kasi; Brandon, Alfred H.; Mahmood, Saleem; Markoe, Arnold M.: The role of hyperfractionated re-irradiation in metastatic brain disease: A single institutional trial, 158

Abella, E. See Varterasian, M.

Achard, Jean-Louis See Ferrière, Jean-Pierre

Adamietz, I. A. See Mose, S.

Adamietz, Ireneus A. See Mose, Stephan

Adams, P. T. See Varterasian, M.

Adelstein, David J. See Tan, Eng-Huat

Advani, S. H. See Kulkarni, S. S.

Ajani, J. See Pazdur, R.

Akutsu, Miyuki See Yokoi, Kohei

Albin, N. See Bachaud, J. M.

Alecover, Juan See Fernández-Conde, Manuel

Al-Katib, A. See Varterasian, M.

Aloe, A. See Nardi, M.

Amista, Pietro See Brandes, Alba Ariela

Anderson, Tom See Chitambar, Christopher R.

Andras, Ellis J. See Komaki, Ritsuko

Andrews, David W. See Glass, Jon

Antoine, Eric-Charles

—Rixe, Olivier; Auclerc, Gérard; Weil, Marise; Khayat, David; Docetaxel: A review of its role in breast cancer treatment, 429

Apostoli, Pietro See Micheletti, Enrico

Aramendia, Jose M. See Aristu, Javier

Arase, Yasuji See Ikeda, Kenji

Ardavanis, Alekos See Kosma, Lambrini

Aristu, Javier

—Rebolledo, José; Martínez-Monge, Rafael; Aramendia, Jose M.; Viera, Juan C.; Azinovic, Ignacio; Herreros, Jesús; Brugarolas, Antonio: Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: Final results of a phase II study, 276

Armstead, Barbara See Vaughn, David J.

Aron, Bernard S. See Barrett, William L.

Asbell, Sucho O. See Komaki, Ritsuko

Asbury, Robert

—Blessing, John A.; Look, Katherine Y.; Buller, Richard; Lucci, Joseph A., III: A phase II trial of amonafide in patients with nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, 626

Athanassiou, A. See Pectasides, D.

Atlante, G. See Nardi, M.

Auclerc, Gérard See Antoine, Eric-Charles

Axelrod, Rita See Glass, Jon

Azinovic, Ignacio See Aristu, Javier

Bachaud, J. M.

—Chatelut, E.; Canal, P.; Albin, N.; Yardeni, E.; David, J. M.; Serrano, E.; Daly-Schweitzer, N.: Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: Results of a phase I study, 1

Baert, Luc See Goethuys, Hans

Baert, Luc See Petrovich, Zbigniew

Bagshaw, Malcolm A. See Petrovich, Zbigniew

Baldini, Editta

—Tibaldi, Carmelo; Lencioni, Monica; Giannessi, Piergiorgio; Evangelista, Giuseppe; Roncella, Manuela; Spinelli, Claudio; Meucci, Claudio; da Prato, Miria; Conte, Pierfranco: Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients, 169

Ballesterro, Alberto

—Ferrando, Fabio; Stura, Paola; Puglisi, Maria; Brema, Fulvio; Patrone, Franco: Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide, and cisplatin (CEP), 266

Barbanti, Ilaro See Cascinu, Stefano

Barrett, William L.

—Gluckman, Jack L.; Aron, Bernard S.: Safety of radiating jejunal interposition grafts in head and neck cancer, 609

Bastin, Kenneth T.

—Steeves, Richard A.; Richards, Marcia J. S.: Radiation therapy for squamous cell carcinoma in dystrophic epidermolysis bullosa: Case reports and literature review, 55

Basurto, Carlo See Colozza, Mariantonietta

Begbie, Stephen D.

—Bell, David R.; Nevell, David F.: Mediastinal epithelioid hemangiopericytoma in a patient with type IV Ehlers-Danlos syndrome: A case report and review of the literature, 412

Bekrada, Mohammed See Culine, Stéphane

Bélembaogo, Ernest See Ferrière, Jean-Pierre

Bell, David R. See Begbie, Stephen D.

Bellini, Andrew See Warner, Ellen

Belsanti, Virginio See Colozza, Mariantonietta

Benhammouda, A. See Rixe, O.

Ben-Yosef, Rami

—Or, Reuven; Naparstek, Ella; Kapelushnik, Joseph; Samuels, Simcha; Slavin, Shimon; Nagler, Arnon: Should soybean agglutinin purging be performed in breast cancer patients undergoing autologous stem cell transplantation? A retrospective analysis of 48 patients, 419

Bernhard, Michael See Mose, Stephan

Bernhart, Bernard See Rafi, Shahin

Beroukas, Kostantinos See Kosma, Lambrini

Berry, John See Ezzat, Adnan A.

Berti, Franco See Brandes, Alba Ariela

Bescos, Socorro See del Campo, Jose M.

Bianchi, Ernestina See Micheletti, Enrico

Bishop, J. F. See Michael, M.

Bishop, James F. See Parnis, Francis X.

Blake, Debbie S. See Jamis-Dow, Carlos A.

Blessing, John A. See Asbury, Robert

Blessing, John A. See Lincoln, Sarah

Blevins, Judith C. See Hong, Jack J.

Blijham, Geert H. See Hupperets, Pierre S.

Blitzer, Peter H. See Rubenstein, James H.

Bodi, Ramon See Felip, Enriqueta

Boisvert, D. See Maroun, J. A.

Borel, C. See Rixe, O.

Böttcher, Heinz D. See Mose, Stephan

Brady, Luther W. See Goethuys, Hans

Brady, Luther W. See Petrovich, Zbigniew

Brandes, Alba Ariela
—Scelzi, Elvira; Zampieri, Paolo; Rigan, Alberto; Rotilio, Antonino; Amista, Pietro; Berti, Franco; Fiorentino, Mario V.: Phase II trial with BCNU plus α -interferon in patients with recurrent high-grade gliomas, 364

Brandon, Alfred H. See Abdel-Wahab, May M. R.

Brema, Fulvio See Ballestrero, Alberto

Briefeld, Philip P. See Montebello, Joseph F.

Broun, E. Randolph
—Iseminger, Karen A.; Rose, Peter G.; Lentz, Samuel L.; Malfetano, John H.; Lincoln, Sarah; Mannel, Robert: A phase II trial of edatrexate in previously treated squamous cell cervical cancer: A Gynecologic Oncology Group study, 78

Brugarolas, Antonio See Aristu, Javier

Buller, Richard See Asbury, Robert

Buzaid, Antonio C. See Sporn, Jonathan R.

Byhardt, Roger W. See Komaki, Ritsuko

Cagna, Emanuela See Micheletti, Enrico

Calabresi, F. See Nardi, M.

Camoriano, John K. See Rajkumar, S. Vincent

Canal, P. See Bachaud, J. M.

Carlson, Grant W. See Hughes, Lorie L.

Carpenter, L. S. See Fishman, A.

Carretero, Pablo See Fernández-Conde, Manuel

Cartel, Giuseppe See Iop, Aldo

Casado, Susana See del Campo, Jose M.

Casado, Susana See Felip, Enriqueta

Cascinu, S.
—Del Ferro, E.; Ligi, M.; Graziano, F.; Catalano, G.: The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer, 477

Catalano, G. See Cascinu, S.

Catalano, Giuseppina See Cascinu, Stefano

Cesarman, Gabriella See Rafi, Shahin

Chang, Hong-Tai
—Mok, King-Tong; Tzeng, Wen-Sheng: Induction intraarterial chemotherapy for T₄ breast cancer through an implantable port-catheter system, 493

Chap, Linnea I.
—Mirra, Joseph; Ippolito, Vincenzo; Rentschler, Robert; Rosen, Peter: Miliary osteosarcomatosis with associated hypocalcemia, 505

Chapman, W. See Siu, L. L.

Charrier, Sabine See Ferrière, Jean-Pierre

Chatelut, E. See Bachaud, J. M.

Chayama, Kazuaki See Ikeda, Kenji

Chitambar, Christopher R.
—Zahir, Syed A.; Ritch, Paul S.; Anderson, Tom: Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma, 173

Chiu, J. K. See Fishman, A.

Cho, Jae Yong See Park, Jooh Oh

Chollet, Philippe See Ferrière, Jean-Pierre

Chung, Hyun Cheol See Park, Jooh Oh

Chung, Hyun Cheol See Park, Joon Oh

Ciesielski-Carlucci, Chris
—Leong, Pat; Jacobs, Charlotte: Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles, 373

Clamon, Gerald H. See Luikart, Sharon D.

Clocchiatti, Luigi See Iop, Aldo

Clohisy, Denis R.
—Le, Chap T.; Umen, Andrew J.: Measuring health status in patients with skeletal metastases treated by surgery, 424

Cobos, Everardo See Keung, Yi-Kong

Coeffic, D. See Rixe, O.

Cognetti, F. See Nardi, M.

Cohen, Neil See Sporn, Jonathan R.

Cohen, Philip R. See Theriault, Alexandra

Coia, Lawrence R. See Fein, Douglas A.

Coleman, Morton See Rafi, Shahin

Colleoni, M.
—Graiff, C.; Nelli, P.; Vicario, G.; Sgarbossa, G.; Pancheri, F.; Manente, P.: Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma, 303

Colleoni, M.
—Graiff, C.; Vicario, G.; Nelli, P.; Sgarbossa, G.; Pancheri, F.; Manente, P.: Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer, 383

Collins, Jerry M. See Jamis-Dow, Carlos A.

Colozza, Mariantonietta
—Mosconi, Anna Maria; Gori, Stephanja; Belsanti, Virginio; Balsutto, Carlo; de Angelis, Verena; Giansanti, Michele; Tonato, Maurizio: Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide, 522

Conte, Pierfranco See Baldini, Editta

Cormio, Gennaro
—Maneo, Andrea; Gabriele, Antonio; Zanetta, Gerardo; Losa, Giuseppa; Lissoni, Andrea: Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin, 143

Corn, Benjamin W. See Glass, Jon

Courtadon, Michel See Ferrière, Jean-Pierre

Courtney, Alice See Nemunaitis, John

Cox, James D. See Komaki, Ritsuko

Cox, James D. See Perkins, Penny

Cox, John See Nemunaitis, John

Crawford, E. David See Kish, Julie A.

Crawford, Jeffrey See Luikart, Sharon D.

Creagan, Edward T.
—Rowland, Kendrith M., Jr.; Suman, Vera J.; Kardinal, Carl G.; Marschke, Robert F., Jr.; Marks, Randolph S.; Maples, William J.: Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma, 490

Cripps, C. See Maroun, J. A.

Culine, Stéphane
—Théodore, Christine; Bekradda, Mohammed; Farhat, Fadi; Terrier-Lacombe, Marie-Josée; Droz, Jean-Pierre: Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA_{II})/vinblastine, bleomycin (VB_{IV}) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors, 184

Curé, Hervé See Ferrière, Jean-Pierre

da Prato, Miria See Baldini, Editta

Dahrouge, S. See Maroun, J. A.

Dahrouge, Simone See Stewart, David J.

Daly-Schweitzer, N. See Bachaud, J. M.

Dauphin, Jean See Rubenstein, James H.

Dauplat, Jacques See Ferrière, Jean-Pierre

David, J. M. See Bachaud, J. M.

Davis, Charles S. See Dreicer, Robert

Davis, Eugene B. See Sharma, Daya

de Angelis, Verena See Colozza, Mariantonietta

Deedy, Matthew See Emami, Bahman

de Filippis, Sandro See Recchia, Francesco

de Filippis, Sandro See Recchia, Francesco

del Campo, Jose M.
—Felip, Enriqueta; Giralt, Jordi; Raspall, Guillermo; Bescos, So-

corro; Casado, Susana; Maldonado, Xavier: Preoperative simultaneous chemoradiotherapy in locally advanced cancer of the oral cavity and oropharynx, 97

Del Campo, Jose M. See Felip, Enriqueta

Del Ferro, E. See Cascinu, S.

Del Ferro, Elena See Cascinu, Stefano

de Latour, Monique See Ferrière, Jean-Pierre

de Marco, S. See Nardi, M.

Dennis, W. See Fishman, A.

Derenne, J. P. See Rixe, O.

Diaz-Canton, E. See Pazdur, R.

Dimitriades, M. See Pectasides, D.

Dodo, Yoshihiro See Sasai, Keisuke

Doggett, R. L. Scott See Leigh, Bryan R.

Donnelly, Elizabeth See Savaraj, Niramol

Doolas, Alexander See Ebie, Nyambi

Dosoretz, Daniel E. See Rubenstein, James H.

Douglass, Harold O., Jr. See Vaughn, David J.

Dragovic, J. See Varterasian, M.

Dreicer, Robert

—Karwal, Mark W.; Midence, Gerardo; Davis, Charles S.; Netleman, Mary: The role of radionuclide angiography in the treatment of patients receiving doxorubicin-based chemotherapy, 132

Dreicer, Robert

—Propert, Kathleen J.; Kuzel, Timothy; Kirkwood, John M.; O'Dwyer, Peter J.; Loehr, Patrick J.: A phase II trial of edatrexate in patients with advanced renal cell carcinoma: An Eastern Cooperative Oncology Group study, 251

Dreicer, Robert See See, William A.

Droughton, Mary Lynn T. See Tan, Eng-Huat

Droz, Jean-Pierre See Culine, Stéphane

Du, W. See Varterasian, M.

Ebie, Nyambi

—Kang, H. Jason; Millikan, Keith; Murthy, Anantha K.; Griem, Kathy; Hartsell, William; Recine, Diane C.; Doolas, Alexander; Taylor, Samuel, IV: Integration of surgery in multimodality therapy for esophageal cancer, 11

Einstein, Albert B. See Kish, Julie A.

Elgammal, Azis See Petrovich, Zbigniew

Elias, S.

—Parker, R. G.; Gallardo, D.; Law, J.: Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate, 120

El-Mahdi, Anas M. See Hong, Jack J.

Eltabbakh, Gamal H. See Hempling, Ronald E.

El-Warith, Ahmed Abd See Ezzat, Adnan A.

Emami, B.

—Kaiser, L.; Simpson, J.; Shapiro, S.; Roper, C.; Lockett, M. A.: Postoperative radiation therapy in non-small cell lung cancer, 441

Emami, Bahman

—Graham, Mary V.; Deedy, Matthew; Shapiro, Susan; Kucik, Nancy: Radiation therapy for intrathoracic recurrence of non-small cell lung cancer, 46

Emami, Bahman See Komaki, Ritsuko

Eskander, Elhamy D.

—Harvey, Harold A.; Givant, Elise; Lipton, Allan: Phase I study combining tumor necrosis factor with interferon- α and interleukin-2, 511

Esper, Peggy S. See Pienta, Kenneth J.

Evangelista, Giuseppe See Baldini, Editta

Ezawa, Kazuhiro See Makimoto, Takeyuki

Ezzat, Adnan A.

—Raja, Madras A.; Berry, John; El-Warith, Ahmed Abd; Khan, Bashir A.; Rhydderch, Dorothy C.: A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma, 179

Falkson, Geoffrey See Ribeiro, Maria

Farhat, Fadi See Culine, Stéphane

Fedeli, Anna See Cascinu, Stefano

Fein, Douglas A.

—Hanlon, Alexandra L.; Lee, W. Robert; Ridge, John A.; Coia, Lawrence R.: Neck failure in T2N0 squamous cell carcinoma of the true vocal cords: The Fox Chase experience and review of the literature, 154

Felip, Enriqueta

—Del Campo, Jose M.; Bodí, Ramon; Vera, Ruth; Casado, Susana; Rubio, Diego: Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients, 404

Felip, Enriqueta See del Campo, Jose M.

Fenessy, A. See Michael, M.

Fernández-Conde, Manuel

—Alcover, Juan; Aaron, Jean E.; Ordi, Jaume; Carretero, Pablo: Skeletal response to clodronate in prostate cancer with bone metastases, 471

Ferrando, Fabio See Ballestrero, Alberto

Ferrière, Jean-Pierre

—Charrier, Sabine; Curé, Hervé; Kwiatkowski, Fabrice; Courtadon, Michel; Bélembaogo, Ernest; de Latour, Monique; Achard, Jean-Louis; Dauplat, Jacques; Chollet, Philippe: Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results, 219

Feun, Lynn See Abdel-Wahab, May M. R.

Feun, Lynn G. See Savaraj, Niramol

Fiorentino, Mario V. See Brandes, Alba Ariela

Fishman, A.

—Chiu, J. K.; Girtanner, R. E.; Dennis, W.; Carpenter, L. S.; Lu, H. H.; Woo, S. Y.; Kerley, J. M.; Kaplan, A. L.: Phase I-II study of combined 5-fluorouracil and cisplatin chemotherapy and altered fractionation radiotherapy for advanced squamous cell carcinoma of the cervix, 342

Fitch, Tom R. See Rajkumar, S. Vincent

Flaherty, Lawrence E.

—Lim, P. Y.; Unger, Joseph; Sondak, Vernon K.: Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma, 600

Flaherty, Lawrence E. See Pienta, Kenneth J.

Flynn, Patricia M. See Sandlund, John T.

Forest, Paula K. See See, William A.

Foroglou, George See Fountzilas, George

Fountzilas, George

—Karavelis, Antonios; Makrantonakis, Paris; Selviaridis, Panayiotis; Tzitzikas, John; Kalogera-Fountzila, Anna; Hatzibaloglou, Ananias; Karkavelas, George; Foroglou, George; Tourkantonis, Achilles: Concurrent radiation and intracarotid cisplatin infusion in malignant gliomas, 138

Frati, Luigi See Recchia, Francesco

Frenkel, Eugene P. See Hughes, Randall S.

Frytak, Stephen See Kochhar, Ruby

Frytak, Stephen See Okuno, Scott H.

Frytak, Stephen See Rajkumar, S. Vincent

Fuki, Naoto See Makimoto, Takeyuki

Fukusato, Toshio See Sakurai, Hideyuki

Gabriele, Antonio See Cormio, Gennaro

Gallardo, D. See Elias, S.

Gannett, Dave E.

—Hill, Donald; Hamilton, Allan J.; Stea, Baldassarre: Paclitaxel as a radiosensitizer combined with fractionated stereotactic radiotherapy in the treatment of recurrent medulloblastoma, 233

García, L. García See López-Muñiz, J. I. Chacón

Gaynor, Mitchell See Rafi, Shahin

Giannessi, Piergiorgio See Baldini, Editta

Giansanti, Michele See Colozza, Mariantonietta

Gilchrist, Gerald S. See O'Mearaigh, Aengus S.

Giralt, Jordi See del Campo, Jose M.

Girtanner, R. E. See Fishman, A.

Givant, Elise See Eskander, Elhamy D.

Glass, Jon

—Silverman, Craig L.; Axelrod, Rita; Corn, Benjamin W.; Andrews, David W.: Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma, 226

Gluckman, Jack L. See Barrett, William L.

Goel, R. See Maroun, J. A.

Goethuys, Hans

—Baert, Luc; Van Poppel, Hein; Lieskovsky, Gary; Brady, Luther W.; Petrovich, Zbigniew: Treatment of metastatic carcinoma of the prostate, 40

Goethuys, Hans See Petrovich, Zbigniew

Gómez, L. López See López-Muñiz, J. I. Chacón

Gopal, R. See Kulkarni, S. S.

Gori, Stephanía See Colozza, Mariantonietta

Graham, Mary V. See Emami, Bahman

Graiff, C. See Colleoni, M.

Graiff, C. See Colleoni, M.

Graziano, F. See Cascinu, S.

Green, Mark R. See Luikart, Sharon D.

Greenberg, Bernard R. See Khan, Amir

Greenberg, Bernard R. See Sporn, Jonathan R.

Greenberg, Harry S. See Kim, H. Katherine

Griem, Kathy See Ebie, Nyambi

Grosfeld, Jay See Montebello, Joseph F.

Grove, W. See Pazdur, R.

Gulino, Alberto See Recchia, Francesco

Haller, Daniel G. See Vaughn, David J.

Hamilton, Allan J. See Gannett, Dave E.

Hanlon, Alexandra L. See Fein, Douglas A.

Haq, Saba See Malik, Intiaz A.

Hara, Nobuyuki See Nakanishi, Yoichi

Harbour, Darlene See Smith, Anthony

Hareyama, Masato See Kagami, Yoshikazu

Hartsell, William See Ebie, Nyambi

Harvey, Harold A. See Eskander, Elhamy D.

Hatzibaloglou, Ananias See Fountzilas, George

Heaton, Diane See Hughes, Lorie L.

Heilman, Hans P. See Petrovich, Zbigniew

Hempling, Ronald E.

—Eltabbakh, Gamal H.; Piver, M. Steven; Recio, Fernando O.; O'Neill, Catherine P.: The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma, 315

Herndon, James E., II See Luikart, Sharon D.

Herreros, Jesús See Aristu, Javier

Heyd, R. See Mose, S.

Hill, Donald See Gannett, Dave E.

Hillen, Harry F. See Hupperets, Pierre S.

Hiraoka, Masahiro See Sasai, Keisuke

Hollis, Donna R. See Luikart, Sharon D.

Holroyde, Christopher See Vaughn, David J.

Honda, Norinari See Inoue, Yusuke

Hong, Jack J.

—Yacoub, Sherif F.; Blevins, Judith C.; Kuban, Deborah A.; El-Mahdi, Anas M.: High dose rate vaginal brachytherapy in early stage endometrial carcinoma: Preliminary analysis, 254

Hsu, Chen-Yi See Lin, Jin-Ching

Hughes, Lorie L.

—Styblo, Toncred M.; Thoms, William W.; Schwarzmann, Stephen W.; Landry, Jerome C.; Heaton, Diane; Carlson, Grant W.; Wood, William C.: Cellulitis of the breast as a complication of breast-conserving surgery and irradiation, 338

Hughes, Randall S.

—Frenkel, Eugene P.: The role of chemotherapy in head and neck cancer, 449

Hupperets, Pierre S.

—Volovics, Lex; Schouten, Leo J.; Jager, Jos J.; Schouten, Harry C.; Hillen, Harry F.; Blijham, Geert H.: The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer, 546

Hussain, Maha H. A. See Kish, Julie A.

Hussain, Mohammed A. See Sharma, Daya

Iacovelli, A. See Nardi, M.

Ibuki, Yoshito See Sakurai, Hideyuki

Ikeda, Kenji

—Saitoh, Satoshi; Suzuki, Yoshiyuki; Koida, Isao; Tsubota, Akihito; Kobayashi, Masahiro; Arase, Yasuji; Chayama, Kazuaki; Murashima, Naoya; Kumada, Hiromitsu: A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization, 202

Ilson, David H. See Saltz, Leonard B.

Imura, George See Yokoi, Kohei

Ingle, James N.

—Twito, Donald I.; Suman, Vera J.; Krook, James E.; Mailliard, James A.; Windschitl, Harold E.; Marschke, Robert F., Jr.: Evaluation of intravenous 6-thioguanine as first-line chemotherapy in women with metastatic breast cancer, 69

Inoue, Yusuke

—Machida, Kikuo; Honda, Norinari; Takagi, Shunji; Ohtake, Tohru; Nishikawa, Junichi; Sasaki, Yasuhito: Effect of angiotensin II on arteriovenous shunting assessed by hepatic arterial perfusion scintigraphy, 237

Inutsuka, Satoru See Nakanishi, Yoichi

Iop, Aldo

—Cartel, Giuseppe; Vigevani, Enrico; Clocchiatti, Luigi; Mansutti, Mauro; Sibau, Angela M.: Mitomycin c, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas, 515

Ippolito, Vincenzo See Chap, Linnea I.

Iseminger, Karen A. See Broun, E. Randolph

Ishigaki, Takashi See Sasai, Keisuke

Ishihara, Sin-ichi See Makimoto, Takeyuki

Ito, Takeshi See Sueyama, Hiroo

Jacobs, Charlotte See Ciesielski-Carlucci, Chris

Jager, Jos J. See Hupperets, Pierre S.

Jamis-Dow, Carlos A.

—Pearl, Michael L.; Watkins, Paul B.; Blake, Debbie S.; Klecker, Raymond W.; Collins, Jerry M.: Predicting drug interactions *in vivo* from experiments *in vitro*: Human studies with paclitaxel and ketoconazole, 592

Jan, Jian-Sheng See Lin, Jin-Ching

Janakiraman, N. See Varterasian, M.

Jatoi, Ismail: Breast cancer: A systemic or local disease?, 536

Jilani, Farida See Khan, Amir

Jingu, Kenichi See Nakamura, Katsumasa

Jones, Raymond See Weiss, Michael D.

Joshita, Takashi See Sakurai, Hideyuki

Junck, Larry See Kim, H. Katherine

Kagami, Yoshikazu

—Nishio, Masamichi; Narimatsu, Naoto; Myoujin, Miyako; Sakurai, Tomoyasu; Hareyama, Masato: Treatment of squamous cell carcinoma of the esophagus with alternating radiotherapy and chemotherapy (cisplatin, methotrexate, and peplomycin), 16

Kaiser, L. See Emami, B.

Kaizu, Motoki See Sueyama, Hiroo

Kalogera-Fountzila, Anna See Fountzilas, George

Kang, H. Jason See Ebie, Nyambi

Kano, Yasuhiko See Yokoi, Kohei

Kapelushnik, Joseph See Ben-Yosef, Rami

Kaplan, A. L. See Fishman, A.

Karanes, C. See Varterasian, M.

Karanes, C. See Varterasian, M.

Karavelis, Antonios See Fountzilas, George

Kardinal, Carl G. See Creagan, Edward T.

Karkavelas, George See Fountzilas, George

Karwal, Mark W. See Dreicer, Robert

Katin, Michael J. See Rubenstein, James H.

Kattah, Jorge C. See Weiss, Michael D.

Kauffman, William See Sandlund, John T.

Kaufmann, Thomas See Rafi, Shahin

Kawasaki, Masayuki See Nakanishi, Yoichi

Kaye, Steven See Khan, Amir

Kelsen, David P. See Saltz, Leonard B.

Kemp, Bonnie L. See Perkins, Penny

Kerley, J. M. See Fishman, A.

Keshavjee, Al-Noor See Warner, Ellen

Keung, Yi-Kong

—Cobos, Everardo; Whitehead, Robert P.; Roberson, Glenn H.: Secondary syringomyelia due to intramedullary spinal cord metastasis: Case report and review of literature, 577

Khan, Amir

—Jilani, Farida; Kaye, Steven; Greenberg, Bernard R.: Aortic wall sarcoma with tumor emboli and peripheral ischemia: Case report with review of literature, 73

Khan, Bashir A. See Ezzat, Adnan A.

Khan, Wajahat A. See Malik, Imtiaz A.

Khayat, D. See Rixe, O.

Khayat, David See Antoine, Eric-Charles

Kim, Byung Soo See Park, Jooh Oh

Kim, Byung Soo See Park, Joon Oh

Kim, Choong Bai See Park, Jooh Oh

Kim, H. Katherine

—Thornton, Allan F.; Greenberg, Harry S.; Page, Michaelyn A.; Junck, Larry; Sandler, Howard M.: Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy, 358

Kim, Joo Hang See Park, Jooh Oh

Kim, Joo Hang See Park, Joon Oh

Kirkels, Wim J. See Petrovich, Zbigniew

Kirkwood, John M. See Dreicer, Robert

Kish, Julie A.

—Wolf, Michael K.; Schellhammer, Paul F.; Hussain, Maha H. A.; Einstein, Albert B.; Crawford, E. David: Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: A Southwest Oncology Group trial, 327

Klecker, Raymond W. See Jamis-Dow, Carlos A.

Knecht, R. See Mose, S.

Kobayashi, Masahiro See Ikeda, Kenji

Kochhar, Ruby

—Frytak, Stephen; Shaw, Edward G.: Survival of patients with extensive small-cell lung cancer who have only brain metastases at initial diagnosis, 125

Koida, Isao See Ikeda, Kenji

Komaki, Ritsuko

—Scott, Charles; Lee, Jin S.; Urtasun, Raul C.; Byhardt, Roger W.; Emami, Bahman; Andras, Ellis J.; Asbell, Sucho O.; Rotman, Marvin; Cox, James D.: Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06, 435

Kosma, Lambrini

—Koukourakis, Michael; Skarlatos, John; Zambatis, Charalambos; Ardashian, Alekos; Beroukas, Kostantinos; Yannakakis, Demetrios: Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer, 562

Kostopoulou, M. See Pectasides, D.

Koukourakis, Michael See Kosma, Lambrini

Krasnow, Steven H. See Sharma, Daya

Krook, James E. See Ingle, James N.

Krzelinski, Reene See Pienta, Kenneth J.

Kuban, Deborah A. See Hong, Jack J.

Kucik, Nancy See Emami, Bahman

Kuerer, Henry

—Shim, Helen; Pertsemidis, Demetrios; Unger, Pamela: Functioning pancreatic acinar cell carcinoma: Immunohistochemical and ultrastructural analyses, 101

Kulkarni, S. S.

—Sastry, P. S. R. K.; Saikia, T. K.; Parikh, P. M.; Gopal, R.; Advani, S. H.: Gonadal function following ABVD therapy for Hodgkin's disease, 354

Kumada, Hiromitsu See Ikeda, Kenji

Kume, Tora See Nakanishi, Ryoichi

Kunitake, Naonobu See Nakamura, Katsumasa

Kuzel, Timothy See Dreicer, Robert

Kwiatkowski, Fabrice See Ferrière, Jean-Pierre

Lackman, Richard D. See Weiss, Arthur J.

la Face, Beniamino See Micheletti, Enrico

Lai, Shenghan See Savaraj, Niramol

Laidlaw, Christine See Parnis, Francis X.

Lalli, Angelo See Recchia, Francesco

Lampidis, Theodore See Savaraj, Niramol

Landry, Jerome C. See Hughes, Lorie L.

Landy, Howard See Abdel-Wahab, May M. R.

Larkin, Edward C. See Leigh, Bryan R.

Lavertu, Pierre See Tan, Eng-Huat

Law, J. See Elias, S.

Le, Chap T. See Clohisy, Denis R.

Lee, Jin S. See Komaki, Ritsuko

Lee, W. Robert See Fein, Douglas A.

Leigh, Bryan R.

—Larkin, Edward C.; Doggett, R. L. Scotte: Solitary extramedullary plasmacytoma five years after successful cardiac transplantation: Case report and review of the literature, 467

Lencioni, Monica See Baldini, Editta

Lentz, Samuel L. See Broun, E. Randolph

Lentz, Samuel S. See Lincoln, Sarah

Leong, Pat See Ciesielski-Carlucci, Chris

Liebmann, James See Smith, Anthony

Lieskovsky, Gary See Goethuys, Hans

Lieskovsky, Gary See Petrovich, Zbigniew

Ligi, M. See Cascinu, S.

Ligi, Marco See Cascinu, Stefano

Lin, Jin-Ching

—Jan, Jian-Sheng; Hsu, Chen-Yi: Pilot study of concurrent chemotherapy and radiotherapy for stage IV nasopharyngeal cancer, 6

Lincoln, Sarah

—Blessing, John A.; McGehee, Ramon; Lentz, Samuel S.: Phase II trial of piroxantrone in advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, 84

Lincoln, Sarah See Broun, E. Randolph

Lipton, Allan See Eskander, Elhamy D.

Lissoni, Andrea See Cormio, Gennaro

Liu, P. Y. See Flaherty, Lawrence E.

Lockett, M. A. See Emami, B.

Loehrer, Patrick J. See Dreicer, Robert

Lokich, Jacob: Spontaneous regression of metastatic renal cancer: Case report and literature review, 416

Look, Katherine Y. See Asbury, Robert

López-Muñiz, J. I. Chacón

—García, L. García; Pérez, C. Lanciego; Mora, M. A. Cruz; Peris, A. García; Martínez, B. Martínez; Gómez, L. López: Treatment of superior and inferior vena cava syndromes of malignant cause with Wallstent catheter placed percutaneously, 293

LoRusso, P. See Rammath, N.

Losa, Giuseppa See Cormio, Gennaro

Lowe, Carl J., Jr.

—Riepe, Stan P.; Wood, William C.: Hepatocellular carcinoma presenting as a pancreatic head mass: Report of an unusual case, 509

Lu, H. H. See Fishman, A.

Lucci, Joseph A., III See Asbury, Robert

Luikart, Sharon D.

—Herndon, James E., II; Hollis, Donna R.; MacDonald, Margaret; Maurer, L. Herbert; Crawford, Jeffrey; Clamon, Gerald H.; Wright, Jonathan; Perry, Michael C.; Ozer, Howard; Green, Mark R.: Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: A Cancer and Leukemia Group B study (CALGB 8832), 24

Lunzer, Steven See Sharma, Daya

Ma, Jinlan See Qin, Dexing

MacDonald, Margaret See Luikart, Sharon D.

Machida, Kikuo See Inoue, Yusuke

Mahmood, Saleem See Abdel-Wahab, May M. R.

Mailliard, James A. See Ingle, James N.

Maitre, B. See Rixe, O.

Makimoto, Takeyuki

—Tsuchiya, Satoshi; Nakano, Hidehiko; Watanabe, Satoru; Minato, Koichi; Takise, Atsushi; Ezawa, Kazuhiro; Fueki, Naoto; Naruse, Ichiro; Nomoto, Taisuke; Takei, Yoshikazu; Ishihara, Sin-ichi; Mori, Masatomo; Saitoh, Ryusei: A phase II study of carboplatin-cisplatin-etoposide combination chemotherapy in advanced non-small-cell lung cancer, 51

Makrantonakis, Paris See Fountzilas, George

Maldonado, Xavier See del Campo, Jose M.

Malftano, John H. See Broun, E. Randolph

Malik, Imtiaz A.

—Khan, Wajahat A.; Haq, Saba; Sabih, Mehreen: A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma, 289

Manente, P. See Colleoni, M.

Manente, P. See Colleoni, M.

Maneo, Andrea See Cormio, Gennaro

Mangano, Mark M. See Rubenstein, James H.

Mannel, Robert See Broun, E. Randolph

Mansutti, Mauro See Iop, Aldo

Manz, Herbert J. See Weiss, Michael D.

Maples, William J. See Creagan, Edward T.

Markoe, Arnold M. See Abdel-Wahab, May M. R.

Marks, Randolph S. See Creagan, Edward T.

Maroun, J. A.

—Cripps, C.; Goel, R.; Dahrude, S.; Boisvert, D.: Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer: The Ottawa experience, 387

Marschke, Robert F., Jr. See Creagan, Edward T.

Marschke, Robert F., Jr. See Ingle, James N.

Martino, S. See Rammath, N.

Martínez, B. Martínez See López-Muñiz, J. I. Chacón

Martínez-Monge, Rafael See Arisztu, Javier

Masuda, Kouji See Nakamura, Katsumasa

Maurer, L. Herbert See Luikart, Sharon D.

McGehee, Ramon See Lincoln, Sarah

Meropol, Neal J. See Vaughn, David J.

Meucci, Claudio See Baldini, Editta

Meyer, Wally See Nemunaitis, John

Meyers, C. See Pazdur, R.

Michael, M.

—Toner, G. C.; Olver, I. N.; Fennessy, A.; Bishop, J. F.: Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer, 259

Micheletti, Enrico

—la Face, Beniamino; Bianchi, Ernestina; Cagna, Emanuela; Apostoli, Pietro; Ruggieri, Giuseppina; Verardi, Rosanna; Sartori, Enrico: Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC): A phase I/II and pharmacokinetic study, 613

Midence, Gerardo See Dreicer, Robert

Millikan, Keith See Ebie, Nyambi

Min, Jin Sik See Park, Joon Oh

Min, Jin Sik See Park, Joon Oh

Minato, Koichi See Makimoto, Takeyuki

Mintzer, David See Vaughn, David J.

Mirra, Joseph See Chap, Linnea I.

Mitsudomi, Tetsuya See Nakanishi, Ryoichi

Mitsuhashi, Norio See Sakurai, Hideyuki

Miyazawa, Naoto See Yokoi, Kohei

Mok, King-Tong See Chang, Hong-Tai

Munobello, Joseph F.

—Papiez, Lech; Siddiqui, Aslam R.; Brieftfeld, Philip P.; Grosfeld, Jay; Scherer, L. R.: Contamination of the pleural surfaces in childhood sarcoma: Use of colloidal P-32 to reduce radiation dose to the whole lung, 587

Moore, M. J. See Siu, L. L.

Mora, M. A. Cruz See López-Muñiz, J. I. Chacón

Mori, Kiyoshi See Yokoi, Kohei

Mori, Masatomo See Makimoto, Takeyuki

Mosconi, Anna Maria See Colozza, Mariantonietta

Mose, S.

—Adamietz, I. A.; Saran, F.; Thilmann, C.; Heyd, R.; Knecht, R.; Böttcher, H. D.: Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis?, 407

Mose, Stephan

—Adamietz, Irenäus A.; Thilmann, Christoph; Saran, Frank; Bernhard, Michael; Pahnke, Ruth; Böttcher, Heinz D.: Bilateral breast carcinoma versus unilateral disease: Review of 498 patients, 541

Mues, Gabriele See Nemunaitis, John

Murashima, Naoya See Ikeda, Kenji

Murthy, Anantha K. See Ebie, Nyambi

Mylonakis, A. See Pectasides, D.

Myoujin, Miyako See Kagami, Yoshikazu

Nagler, Arnon See Ben-Yosef, Rami

Nakamura, Katsumasa

—Uehara, Satoru; Omagari, Junichi; Kunitake, Naonobu; Jingu, Kenichi; Masuda, Kouji: Primary non-Hodgkin's lymphoma of the maxillary sinus, 272

Nakanishi, Ryoichi

—Kume, Toru; Mitsudomi, Tetsuya; Yoshimatsu, Takashi; Osaki, Toshihiro; Tokunaga, Hiroyuki; Yasumoto, Kosei: Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer, 31

Nakanishi, Yoichi

—Takayama, Koichi; Kawasaki, Masayuki; Yatsunami, Jun; Inutsuka, Satoru; Wakamatsu, Kentaro; Tsuruta, Nobuko; Hara, Nobuyuki: Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer, 393

Nakano, Hidehiko See Makimoto, Takeyuki

Naparstek, Ella See Ben-Yosef, Rami

Nardi, M.

—Aloe, A.; de Marco, S.; Cognetti, F.; Iacovelli, A.; Atlante, G.;

Calabresi, F.: Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: A phase II study, 230

Narimatsu, Naoto See Kagami, Yoshikazu

Naruse, Ichirou See Makimoto, Takeyuki

Nelli, P. See Colleoni, M.

Nelli, P. See Colleoni, M.

Nemunaitis, John
—Cox, John; Meyer, Wally; Courtney, Alice; Mues, Gabriele: Irinotecan hydrochloride (CPT-11) resistance identified by *K-ras* mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU), 527

Nettlemann, Mary See Dreicer, Robert

Nevell, David F. See Begbie, Stephen D.

Niibe, Hideo See Sakurai, Hideyuki

Niitsu, Nozomi
—Umeda, Masanori: Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma, 311

Nilsson, Bo See Rosenfeld, Craig S.

Nishikawa, Junichi See Inoue, Yusuke

Nishimaki, Tadashi See Sueyama, Hiroo

Nishio, Masamichi See Kagami, Yoshikazu

Noh, Sung Hoon See Park, Jooh Oh

Nomoto, Taisuke See Makimoto, Takeyuki

Nuamah, Isaac See Vaughn, David J.

Nuzzo, Antonio See Recchia, Francesco

O'Dwyer, Peter J. See Dreicer, Robert

Ohtake, Tohru See Inoue, Yusuke

Okuno, Scott H.
—Frytak, Stephen: Mitomycin lung toxicity: Acute and chronic phases, 282

Olver, I. N. See Michael, M.

Olver, Ian N. See Parnis, Francis X.

Omagari, Junichi See Nakamura, Katsumasa

O'Meara, Aengus S.
—Gilchrist, Gerald S.: Dose reduction of chemotherapeutic agents after weight loss, 193

O'Neill, Catherine P. See Hempling, Ronald E.

Or, Reuven See Ben-Yosef, Rami

Orcel, B. See Rixe, O.

Ordi, Jaume See Fernández-Conde, Manuel

Osaki, Toshihiro See Nakanishi, Ryoichi

Osborn, Jennifer L.
—Smith, David C.; Trump, Donald L.: Megestrol acetate in the treatment of hormone refractory prostate cancer, 308

Ozer, Howard See Luikart, Sharon D.

Page, Michaelyn A. See Kim, H. Katherine

Pahnke, Ruth See Mose, Stephan

Pancheri, F. See Colleoni, M.

Pancheri, F. See Colleoni, M.

Papadopoulou, M. See Pectasides, D.

Papiez, Lech See Montebello, Joseph F.

Papish, Steven W. See Rafi, Shahin

Parikh, P. M. See Kulkarni, S. S.

Park, Jooh Oh
—Chung, Hyun Cheol; Cho, Jae Yong; Rha, Sun Young; You, Nae Choon; Kim, Joo Hang; Noh, Sung Hoon; Kim, Choong Bai; Min, Jin Sik; Kim, Byung Soo; Roh, Jae Kyung: Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-c (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer, 484

Park, Joon Oh
—Rha, Sun Young; Yoo, Nae Choon; Kim, Joo Hang; Roh, Jae Kyung; Min, Jin Sik; Kim, Byung Soo; Chung, Hyun Cheol: A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy, 569

Parker, R. G. See Elias, S.

Parnis, Francis X.
—Olver, Ian N.; Sandeman, Tom; Bishop, James F.; Laidlaw, Christine: A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer, 319

Patrone, Franco See Ballestrero, Alberto

Patt, Y. See Pazdur, R.

Paulino, Arnold C. **The location of the prostatic apex on retrograde urethrography and its relationship to the bottom of the ischial tuberosities, 479**

Pazdur, R.
—Meyers, C.; Diaz-Canton, E.; Abbruzzese, J. L.; Patt, Y.; Grove, W.; Ajani, J.: Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma: Model for prospective evaluation of neurotoxicity, 573

Pearl, Michael L. See Jamis-Dow, Carlos A.

Pectasides, D.
—Mylonakis, A.; Kostopoulou, M.; Papadopoulou, M.; Triantafyllis, D.; Varthalitis, J.; Dimitriades, M.; Athanassiou, A.: CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma, 348

Pensa, Floriana See Pronzato, Paolo

Pérez, C. Lanciego See López-Muñiz, J. I. Chacón

Perez, Carlos A. See Petrovich, Zbigniew

Peris, A. García See López-Muñiz, J. I. Chacón

Perkins, Penny
—Kemp, Bonnie L.; Putnam, Joe B., Jr.; Cox, James D.: Pretreatment characteristics of carcinoid tumors of the lung which predict aggressive behavior, 285

Perry, Michael C. See Luikart, Sharon D.

Pertsemidis, Demetrios See Kuerer, Henry

Petit, T. See Rixe, O.

Petrovich, Zbigniew
—Baert, Luc; Bagshaw, Malcolm A.; Brady, Luther W.; Elgamal, Azis; Goethuys, Hans; Heilman, Hans P.; Kirkels, Wim J.; Lieskovsky, Gary; Perez, Carlos A.; Van Poppel, Hein; Williams, Richard D.: Adenocarcinoma of the prostate: Innovations in management, 111

Petrovich, Zbigniew See Goethuys, Hans

Pienta, Kenneth J.
—Esper, Peggy S.; Zwas, Fred; Krzeminski, Reene; Flaherty, Lawrence E.: Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate, 36

Piver, M. Steven See Hempling, Ronald E.

Pronzato, Paolo
—Vigani, Antonella; Pensa, Floriana; Vanoli, Maurizio; Tani, Francesco; Vaira, Franco: Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer, 519

Proper, Kathleen J. See Dreicer, Robert

Puglisi, Maria See Ballestrero, Alberto

Putnam, Joe B., Jr. See Perkins, Penny

Qin, Dexing
—Ma, Jinlan; Xiao, Jianping; Tang, Zhiqiang: Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents, 263

Quaglino, Dennis See Recchia, Francesco

Quan, Valerie See Saltz, Leonard B.

Rafi, Shahin
—Coleman, Morton; Kaufmann, Thomas; Cesarman, Gabriella; Papish, Steven W.; Bernhart, Bernard; Gaynor, Mitchell; Reisman, Arlene M.: COBLAM IV chemotherapy of large cell lymphoma: Sequential use of infusional vincristine and bleomycin and "high dose" consolidation, 90

Raja, Madras A. See Ezzat, Adnan A.

Rajkumar, S. Vincent

—Frytak, Stephen; Rubin, Joseph; Camoriano, John K.; Fitch, Tom R.: Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: A phase I trial, 500

Raman, S. B. K. See Varterasian, M.

Ramnath, N.

—LoRusso, P.; Simon, M.; Martino, S.: Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer, 368

Raspall, Guillermo See del Campo, Jose M.

Ratanatharathorn, V. See Varterasian, M.

Raub, William See Abdel-Wahab, May M. R.

Rea, Silvio See Recchia, Francesco

Rebollo, José See Aristu, Javier

Recchia, Francesco

—de Filippis, Sandro; Torchio, Pierfederico; Rea, Silvio; Gulino, Alberto; Quaglino, Dennis; Frati, Luigi: Randomized trial of ifosfamide vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: A phase I pilot study, 209

Recchia, Francesco

—Nuzzo, Antonio; Lalli, Angelo; de Filippis, Sandro; Torchio, Pierfederico: Activity of standard-dose carboplatin, cyclophosphamide, and etoposide in patients with metastatic breast cancer with previous exposure to anthracyclines, 166

Recine, Diane C. See Ebie, Nyambi

Recio, Fernando O. See Hempling, Ronald E.

Reisman, Arlene M. See Rafi, Shahin

Rentschler, Robert See Chap, Linnea I.

Rha, Sun Young See Park, Joon Oh

Rha, Sun Young See Park, Joon Oh

Rhydderch, Dorothy C. See Ezzat, Adnan A.

Ribeiro, Maria

—Ruff, Paul; Falkson, Geoffrey: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer, 605

Richards, Marcia J. S. See Bastin, Kenneth T.

Ridge, John A. See Fein, Douglas A.

Riepe, Stan P. See Lowe, Carl J., Jr.

Riggs, Charles See See, William A.

Rigon, Alberto See Brandes, Alba Ariela

Ritch, Paul S. See Chitambar, Christopher R.

Rixe, O.

—Coeffic, D.; Orcel, B.; Maitre, B.; Borel, C.; Benhannouda, A.; Petit, T.; Khayat, D.; Derenne, J. P.: A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer, 128

Rixe, Olivier See Antoine, Eric-Charles

Roberson, Glenn H. See Keung, Yi-Kong

Robert, Francisco

—Soong, Seng-jaw; Wheeler, Richard H.: A phase II study of topotecan in patients with recurrent head and neck cancer: Identification of an active new agent, 298

Roh, Jae Kyung See Park, Joon Oh

Roh, Jae Kyung See Park, Joon Oh

Roncella, Manuela See Baldini, Editta

Roper, C. See Emami, B.

Rose, Peter G. See Broun, E. Randolph

Rosen, Peter See Chap, Linnea I.

Rosenfeld, Craig S.

—Zeigler, Zella R.; Shadduck, Richard K.; Nilsson, Bo: Phase II study of roquinimex in myelodysplastic syndrome, 189

Rotilio, Antonino See Brandes, Alba Ariela

Rotman, Marvin See Komaki, Ritsuko

Rowland, Kendrith M., Jr. See Creagan, Edward T.

Rubenstein, James H.

—Katin, Michael J.; Mangano, Mark M.; Dauphin, Jean; Salenius, Sharon A.; Dosoretz, Daniel E.; Blitzer, Peter H.: Small cell ana-

plastic carcinoma of the prostate: Seven new cases, review of the literature, and discussion of a therapeutic strategy, 376

Rubin, Joseph See Rajkumar, S. Vincent

Rubio, Diego See Felipe, Enriqueta

Ruff, Paul See Ribeiro, Maria

Ruggeri, Giuseppina See Micheletti, Enrico

Sabih, Mehreen See Malik, Intiaz A.

Sagerman, Robert H. See Whipple, Gary L.

Sakia, T. K. See Kulkarni, S. S.

Saitoh, Ryusei See Makimoto, Takeyuki

Saitoh, Satoshi See Ikeda, Kenji

Sakai, Kunio See Sueyama, Hiroo

Sakurai, Hideyuki

—Mitsuhashi, Norio; Ibuki, Yoshito; Joshi, Takashi; Fukusato, Toshio; Niibe, Hideo: Placental metastasis from maternal primitive neuroectodermal tumor, 628

Sakurai, Tomoyasu See Kagami, Yoshikazu

Salenius, Sharon A. See Rubenstein, James H.

Saltz, Leonard B.

—Schwartz, Gary K.; Ilson, David H.; Quan, Valerie; Kelsen, David P.: A phase II study of topotecan administered five times daily in patients with advanced gastric cancer, 621

Samuels, Simcha See Ben-Yosef, Rami

Sandeman, Tom See Parnis, Francis X.

Sandler, Howard M. See Kim, H. Katherine

Sandlund, John T.

—Kauffman, William; Flynn, Patricia M.: *Strongyloides stercoralis* infection mimicking relapse in a child with small noncleaved cell lymphoma, 215

Saran, F. See Mose, Stephan

Sartori, Enrico See Micheletti, Enrico

Sasaki, Keisuke

—Yamabe, Hirohiko; Tsutsui, Kazushige; Dodo, Yoshihiro; Ishigaki, Takashi; Shibamoto, Yuta; Hiraoka, Masahiro: Primary testicular non-Hodgkin's lymphoma: A clinical study and review of the literature, 59

Sasaki, Yasuhito See Inoue, Yusuke

Sastray, P. S. R. K. See Kulkarni, S. S.

Savaraj, Niramol

—Wu, Chun Jing; Xu, Rong; Lampidis, Theodore; Lai, Shenghan; Donnelly, Elizabeth; Solomon, Jeanine; Feun, Lynn G.: Multi-drug-resistant gene expression in small-cell lung cancer, 398

Selzli, Elvira See Brandes, Alba Ariela

Schellhammer, Paul F. See Kish, Julie A.

Scherer, L. R. See Montebello, Joseph F.

Schouten, Harry C. See Hupperets, Pierre S.

Schouten, Leo J. See Hupperets, Pierre S.

Schwartz, Gary K. See Saltz, Leonard B.

Schwarzmann, Stephen W. See Hughes, Lorie L.

Scott, Charles See Komaki, Ritsuko

See, William A.

—Dreicer, Robert; Forest, Paula K.; Riggs, Charles: Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: A phase I-II trial, 331

Elviaridis, Panayiotis See Fountzilas, George

Sensenbrenner, L. See Varterasian, M.

Serrano, E. See Bachaud, J. M.

Sgarbossa, G. See Colleoni, M.

Sgarbossa, G. See Colleoni, M.

Shadduck, Richard K. See Rosenfeld, Craig S.

Shapiro, S. See Emami, B.

Shapiro, Susan See Emami, Bahman

Sharma, Daya

—Krasnow, Steven H.; Davis, Eugene B.; Lunzer, Steven; Hussain, Mohammed A.; Wadleigh, Robert G.: Sequential chemotherapy and radiotherapy for squamous cell esophageal carcinoma, 151

Shaw, Edward G. See Kochhar, Ruby

Shibamoto, Yuta See Sasai, Keisuke

Shim, Helen See Kuerer, Henry

Shupak, Rachel See Warner, Ellen

Sibau, Angela M. See Iop, Aldo

Siddiqui, Aslam R. See Montebello, Joseph F.

Silver, S. M. See Varterasian, M.

Silverman, Craig L. See Glass, Jon

Simon, M. See Rammath, N.

Simpson, J. See Emami, B.

Siu, L. L.

- Chapman, W.; Moore, M. J.: Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor: Case report, 558

Skarlatos, John See Kosma, Lambriini

Slater, Dennis See Sporn, Jonathan R.

Slavin, Shimon See Ben-Yosef, Rami

Smith, Anthony

- Harbour, Darlene; Liebmann, James: Acute renal failure in a patient receiving treatment with suramin, 433

Smith, David C. See Osborn, Jennifer L.

Solari, Paul G. See Tay, Jonathan S.

Solomon, Jeanine See Savaraj, Niramol

Sondak, Vernon K. See Flaherty, Lawrence E.

Soong, Seng-jaw See Robert, Francisco

Spinelli, Claudio See Baldini, Editta

Sporn, Jonathan R.

- Buzaid, Antonio C.; Slater, Dennis; Cohen, Neil; Greenberg, Bernard R.: Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon- α -2b, and cisplatin, 81

Sridhar, Kasi See Abdel-Wahab, May M. R.

Stea, Baldassarre See Gannett, Dave E.

Steeves, Richard A. See Bastin, Kenneth T.

Stewart, David J.

- Dahrouge, Simone: Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate: A case report, 381

Stura, Paola See Ballestrero, Alberto

Styblo, Toncred M. See Hughes, Lorie L.

Sueyama, Hiroo

- Sakai, Kunio; Sugita, Tadashi; Ito, Takeshi; Uematsu, Takayoshi; Nishimaki, Tadashi; Kaizu, Motoki: Neoadjuvant chemotherapy followed by concurrent chemotherapy and radiotherapy for locally advanced esophageal carcinoma with bulky upper abdominal lymphadenopathy: Case report, 580
- Sugita, Tadashi See Sueyama, Hiroo

Suman, Vera J. See Creagan, Edward T.

Suman, Vera J. See Ingle, James N.

Suzuki, Yoshiyuki See Ikeda, Kenji

Takagi, Shunji See Inoue, Yusuke

Takayama, Koichi See Nakanishi, Yoichi

Takei, Yoshikazu See Makimoto, Takeyuki

Takise, Atsushi See Makimoto, Takeyuki

Tan, Eng-Huat

- Adelstein, David J.; Droughton, Mary Lynn T.; Van Kirk, Marjorie A.; Lavertu, Pierre: Squamous cell head and neck cancer in nonsmokers, 146

Tang, Zhiqiang See Qin, Dexing

Tani, Francesco See Pronzato, Paolo

Tapen, Elizabeth M. See Tay, Jonathan S.

Tay, Jonathan S.

- Tapen, Elizabeth M.; Solari, Paul G.: Malignant eccrine spiradenoma: Case report and review of the literature, 552

Taylor, Samuel, IV See Ebie, Nyambi

Terrier-Lacombe, Marie-Josée See Culine, Stéphanie

Théodore, Christine See Culine, Stéphanie

Theriault, Alexandra

- Cohen, Philip R.: Herpetic geographic glossitis in a pediatric patient with acute myelogenous leukemia, 567

Thilmann, C. See Mose, S.

Thilmann, Christoph See Mose, Stephan

Thomas, Charles R., Jr.

- Weiden, Paul L.; Traverso, L. William; Thompson, Tove: Concomitant intraarterial cisplatin, intravenous 5-fluorouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: A phase II study of the Puget Sound Oncology Consortium (PSOC-703), 161

Thompson, Tove See Thomas, Charles R., Jr.

Thoms, William W. See Hughes, Lorie L.

Thornton, Allan F. See Kim, H. Katherine

Tibaldi, Carmelo See Baldini, Editta

Tokunaga, Hiroyuki See Nakanishi, Ryoichi

Tominaga, Keigo See Yokoi, Kohei

Tomato, Maurizio See Colozza, Mariantonietta

Tomer, G. C. See Michael, M.

Torchio, Pierfederico See Recchia, Francesco

Torchio, Pierfederico See Recchia, Francesco

Tourkantonis, Achilles See Fountzilas, George

Traverso, L. William See Thomas, Charles R., Jr.

Triantafyllis, D. See Pectasides, D.

Trump, Donald L. See Osborn, Jennifer L.

Tsubota, Akihito See Ikeda, Kenji

Tsuchiya, Satoshi See Makimoto, Takeyuki

Tsuruta, Nobuko See Nakanishi, Yoichi

Tsutsui, Kazushige See Sasai, Keisuke

Twito, Donald L. See Ingle, James N.

Tzeng, Wen-Sheng See Chang, Hong-Tai

Tzitzikas, John See Fountzilas, George

Uberti, J. See Varterasian, M.

Uehara, Satoru See Nakamura, Katsumasa

Uematsu, Takayoshi See Sueyama, Hiroo

Umeda, Masanori See Niitsu, Nozomi

Umen, Andrew J. See Clohisy, Denis R.

Unger, Joseph See Flaherty, Lawrence E.

Unger, Pamela See Kuerer, Henry

Urtasun, Raul C. See Komaki, Ritsuko

Vaira, Franco See Pronzato, Paolo

Van Kirk, Marjorie A. See Tan, Eng-Huat

Vanoli, Maurizio See Pronzato, Paolo

Van Poppel, Hein See Goethuys, Hans

Van Poppel, Hein See Petrovich, Zbigniew

Van Rooy, Eric M. See Whipple, Gary L.

Varterasian, M.

- Janakiraman, N.; Karanes, C.; Abella, E.; Uberti, J.; Dragovic, J.; Raman, S. B. K.; Al-Katib, A.; Du, W.; Silver, S. M.; Adams, P. T.; Sensenbrenner, L.; Ratanathathorn, V.: Transplantation in patients with multiple myeloma: A multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant, 462

Varthalitis, J. See Pectasides, D.

Vaughn, David J.

- Meropol, Neal J.; Holroyde, Christopher; Mintzer, David; Numan, Isaac; Armstead, Barbara; Douglass, Harold O., Jr.; Haller, Daniel G.: A phase II study of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma: A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program trial, 242

Vera, Ruth See Felip, Enriqueta

Verardi, Rosanna See Micheletti, Enrico

Vicario, G. See Colleoni, M.
Vicario, G. See Colleoni, M.
Viera, Juan C. See Aristu, Javier
Vigani, Antonella See Pronzato, Paolo
Vigevani, Enrico See Iop, Aldo
Volovics, Lex See Hupperets, Pierre S.

Wadleigh, Robert G. See Sharma, Daya
Wakamatsu, Kentaro See Nakanishi, Yoichi
Warner, Ellen
 —Keshavjee, Al-Noor; Shupak, Rachel; Bellini, Andrew: Rheumatic symptoms following adjuvant therapy for breast cancer, 322

Watanabe, Satoru See Makimoto, Takeyuki
Watkins, Paul B. See Jamis-Dow, Carlos A.
Weiden, Paul L. See Thomas, Charles R., Jr.
Weil, Marise See Antoine, Eric-Charles
Weiss, Arthur J.
 —Lackman, Richard D.: Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: Advantages and limitations, 63

Weiss, Michael D.
 —Kattah, Jorge C.; Jones, Raymond; Manz, Herbert J.: Isolated facial nerve palsy from metastasis to the temporal bone: Report of two cases and a review of the literature, 19

Wheeler, Richard H. See Robert, Francisco
Whipple, Gary L.
 —Sagerman, Robert H.; Van Rooy, Eric M.: Long-term evaluation of postorchietomy radiotherapy for stage II seminoma, 196

Whitehead, Robert P. See Keung, Yi-Kong
Williams, Richard D. See Petrovich, Zbigniew
Wilson, J. Frank: American Radium Society, 1916-1995: Years of distinction (Hartman Centennial Lecture), 530

Windschitl, Harold E. See Ingle, James N.
Wolf, Michael K. See Kish, Julie A.
Wolfson, Aaron H. See Abdel-Wahab, May M. R.
Woo, S. Y. See Fishman, A.
Wood, William C. See Hughes, Lorie L.
Wood, William C. See Lowe, Carl J., Jr.
Wright, Jonathan See Luikart, Sharon D.
Wu, Chun Jing See Savaraj, Niramol

Xiao, Jianping See Qin, Dexing
Xu, Rong See Savaraj, Niramol

Yacoub, Sherif F. See Hong, Jack J.
Yamabe, Hirohiko See Sasai, Keisuke
Yannakakis, Demetrios See Kosma, Lambrini
Yardeni, E. See Bachaud, J. M.
Yasumoto, Kosei See Nakanishi, Yoichi
Yatsunami, Jun See Nakanishi, Yoichi
Yokoi, Kohei
 —Miyazawa, Naoto; Kano, Yasuhiko; Akutsu, Miyuki; Mori, Kiyoshi; Tominaga, Keigo; Imura, George: Tumor lysis syndrome in invasive thymoma with peripheral blood T-cell lymphocytosis, 86

Yoo, Nae Choon See Park, Joon Oh
Yoshimatsu, Takashi See Nakanishi, Yoichi
You, Nae Choon See Park, Joon Oh

Zahir, Syed A. See Chitambar, Christopher R.
Zalupski, M. See Varterasian, M.
Zambatis, Charalambos See Kosma, Lambrini
Zampieri, Paolo See Brandes, Alba Ariela
Zanetta, Gerardo See Cormio, Gennaro
Zeigler, Zella R. See Rosenfeld, Craig S.
Zwas, Fred See Pienta, Kenneth J.

SUBJECT INDEX

ABVD (doxorubicin-bleomycin-vinblastine-dacarbazine)
for Hodgkin's disease, gonadal function, 354

Acinar cell carcinoma
pancreatic, immunohistochemistry and ultrastructure, 101

Adriamycin
and cyclophosphamide-cisplatin treatment, for Fallopian tube carcinoma, 143
in FLAP. *See* FLAP.

Age factors
non-Hodgkin's lymphoma, POCA and VEC-POB chemotherapy, 179
non-Hodgkin's lymphoma, relapsing or refractory, oral low-dose etoposide effects, 311
and serum testosterone, in metastatic prostate cancer, 605
teniposide effects in small-cell lung cancer, 477

American Radium Society, 1916-1995: Years of Distinction Hartman Centennial Lecture, 530

Amonafide
for nonsquamous cell carcinoma of cervix, 626

Anaphylaxis
from cisplatin/paclitaxel, hypersensitivity reaction profiles, 373

Angiocardiography
radioisotope, and doxorubicin-based chemotherapy, 132

Angiotensin II
and arteriovenous shunting, hepatic arterial perfusion scintigraphy, 237

Announcements, 108, 217

Antigens
prostate-specific, 111

Aortic wall sarcoma
with tumor emboli and peripheral ischemia, 73

Arterial embolization
transcatheter, 5'-DFUR for hepatocellular carcinoma, 202

Arteriovenous shunting
angiotsin II effects, hepatic arterial perfusion scintigraphy, 237

Astrocytoma, malignant
fractionated stereotactic radiotherapy, with cisplatin, 226

Atherosclerosis
and aortic wall sarcoma, 73

BCNU
and α -interferon, high-grade gliomas, 364

BEP (bleomycin-etoposide-cisplatin)
and CISCA_{II}/VB_{IV} regimens, germ cell tumors, 184

Bladder cancer
advanced, outpatient ifosfamide treatment, 519
advanced/recurrent transitional cell, 5-fluorouracil-cisplatin infusion, 327
cisplatin and interferon alpha 2b, 319
doxorubicin, intravesical infusion, phase I-II trials, 331

Bleomycin
See also BEP/VB_{IV}.
ABVD. *See* ABVD.

and COBLAM IV chemotherapy, for large cell lymphoma, 90
and ifosfamide, addition to cisplatin-ifosfamide, for cervical carcinoma, 315

Blood-CSF barrier
permeability of chemotherapeutic agents, effect of brain irradiation, 263

Body surface area
dose reduction of chemotherapeutic agents, after weight loss, 193

Bone metastasis
health status, 424
in prostate cancer, clodronate effects, 471

Bone marrow
allogeneic transplantation, for multiple myeloma, 462

Brachytherapy
for prostate cancer, 111
vaginal, in endometrial carcinoma, 254

Brain metastases
from breast and lung adenocarcinoma, 303
in small-cell lung cancer, 125

Brain tumors
astrocytoma, fractionated stereotactic radiotherapy, and cisplatin, 226
irradiation effects on blood-CSF barrier permeability of chemotherapeutic agents, 263
metastatic, hyperfractionated re-irradiation, 158
re-irradiation with three-dimensional conformal therapy, 358

Breast cancer
bilateral vs. unilateral disease, 541
brain metastasis, combination chemotherapy, 303
docetaxel treatment, 429
doxorubicin as adjuvant chemotherapy, 219
far-advanced, hypofractionated radiotherapy, 5-fluorouracil radiosensitization, 562
high-risk, filgrastim and adjuvant chemotherapy, 169
induction intraarterial chemotherapy, implantable port-catheter system, 493
metastatic, carboplatin-cyclophosphamide-etoposide, after anthracycline therapy, 166
metastatic, cisplatin and WR2721, 368
rheumatic symptoms after adjuvant chemotherapy, 322
soybean agglutinin purging, and autologous stem cell transplantation, 419
steroid receptor activity, 546
surgery and irradiation, cellulitis as complication, 338
systemic or local disease, 536
6-thioguanine treatment, 69

Camptothecin
analogue topotecan, for advanced gastric cancer, 621

Carboplatin
and cisplatin, for non-small cell lung cancer, 31
and cisplatin with vindesine, for non-small cell lung cancer, 393
and cisplatin-etoposide, in advanced malignancy, 500
and cisplatin-etoposide, for non-small cell lung cancer, 51
and cyclophosphamide-etoposide, metastatic breast cancer after anthracycline therapy, 166
and filgrastim vs. sequential filgrastim and molgramostim, 209
with GM-CSF-etoposide, for small-cell lung cancer, 24
during radiotherapy, in cervical carcinoma, 613

Carcinoid tumors
 encephalopathy, octreotide acetate treatment, 558
 of lung, prognostic factors, 285

CEA, CA 19-9, and CA-50
 in monitoring gastric carcinoma, 348

Cellulitis
 from breast-conserving surgery and irradiation, 338

Central nervous system tumors
 gliomas, BCNU and interferon alpha, 3634

CEP (cyclophosphamide–etoposide–cisplatin)
 high-dose therapy, with rhG-CSF, 266

Cervical cancer
 bleomycin–ifosfamide addition to cisplatin–ifosfamide, 315
 carboplatin infusion during radiotherapy, 613
 non-squamous cell carcinoma, amonafide treatment, 626
 squamous cell carcinoma, cisplatin–5-fluorouracil and
 fractionation radiotherapy, phase I-II study, 342
 squamous cell carcinoma, edatrexate therapy, 78
 squamous cell carcinoma, piroxantrone treatment, 84

Chemotherapy
 See also individual agents.
 adjuvant, and concurrent, with radiotherapy, esophageal
 carcinoma with upper abdominal lymphadenopathy, 580
 adjuvant, and filgrastim, for high-risk breast cancer, 169
 adjuvant, 5'-DFUR for hepatocellular carcinoma, 202
 adjuvant, doxorubicin for breast cancer, 219
 adjuvant, rheumatic symptoms in breast cancer, 322
 BEP and CISCA_{II}/VB_{IV}, for germ cell tumors, 184
 and blood-CSF barrier permeability, effect of brain irradiation,
 263
 brain metastases from breast and lung adenocarcinoma, 303
 carboplatin–cisplatin, for non-small cell lung cancer, 31
 carboplatin–cisplatin–etoposide, in advanced non-small cell
 lung cancer, phase II study, 51
 carboplatin–cyclophosphamide–etoposide, metastatic breast
 cancer after anthracycline therapy, 166
 carboplatin–GM-CSF–etoposide, for small-cell lung cancer, 24
 cisplatin–5-FU–leucovorin–etoposide, for non-small cell lung
 cancer, 128
 CODBLAM IV, for large cell lymphoma, infusional vincristine
 and bleomycin and “high-dose” consolidation, 90
 concurrent, with hyperfractionated radiotherapy, for non-small
 cell lung cancer, 435
 and concurrent radiotherapy, for nasopharyngeal cancer, 6
 dose reduction after weight loss, 193
 emesis induced by, intravenous granisetron vs. intravenous and
 oral ondansetron, 569
 filgrastim vs. sequential filgrastim and molgramostim, after
 carboplatin, cyclophosphamide, and etoposide, 209
 5-fluorouracil–leucovorin–interferon- α -2b–cisplatin, for
 pancreatic adenocarcinoma, 81
 for head and neck cancer, 449
 induction intraarterial, for breast cancer, implantable port-
 catheter system, 493
 infusional doxorubicin or ifosfamide, with recombinant human
 granulocyte colony stimulating factor, 63
 intraarterial, angiogenesis II effects on arteriovenous shunting,
 237
 mediastinal epithelioid hemangioendothelioma, in Ehlers–
 Danlos syndrome, 412
 for metastatic prostate cancer, 40
 POCA and VEC-POB, for non-Hodgkin's lymphoma, 179
 and radiotherapy, for cancer of oral cavity and oropharynx, 97
 and radiotherapy, sequential, for squamous cell esophageal
 carcinoma, 151
 radiotherapy and surgery, for esophageal cancer, 11
 for sarcoma, and leukemia heterogeneity, 585

Children
 herpetic geographic glossitis, with myelogenous leukemia, 567
 pulmonary sarcoma, colloidal P-32 to reduce radiation dose,
 587

CI-980 (NSC 370147)
 for colorectal carcinoma, 573

CISCA_{II} (cisplatin–cyclophosphamide–doxorubicin)
 and BEP, germ cell tumors, 184

Cisplatin
 See also BEP; CISCA_{II}.
 alternating with radiotherapy, for esophageal cancer, 16
 and carboplatin, for non-small cell lung cancer, 31
 and carboplatin with vindesine, for non-small cell lung cancer,
 393
 and carboplatin–etoposide, for non-small cell lung cancer, 51
 and carboplatin–etoposide, in advanced malignancy, 500
 CEP. See CEP.
 and concurrent radiotherapy, for nasopharyngeal cancer, 6
 and cyclophosphamide–adriamycin treatment, for Fallopian
 tube carcinoma, 143
 and doxorubicin–cyclophosphamide treatment, for epithelial
 ovarian carcinoma, 522
 in FLAP. See FLAP.
 and 5-fluorouracil, continuous infusion in bladder cancer, 327
 and 5-fluorouracil, and fractionation radiotherapy, for cervical
 cancer, 342
 and 5-fluorouracil, and split-course radiotherapy, pancreatic
 carcinoma, 161
 5-fluorouracil–leucovorin–etoposide, for non-small cell lung
 cancer, 128
 and fractionated stereotactic radiotherapy, for malignant
 astrocytoma, 226
 and ifosfamide, addition of bleomycin–ifosfamide, for cervical
 carcinoma, 315
 and interferon alpha 2b, in bladder cancer, phase II study, 319
 intracarotid, concurrent radiation, for malignant gliomas, 138
 and leucovorin–5-FU–interferon- α -2b, for pancreatic
 adenocarcinoma, 81
 and mitomycin C–5-fluorouracil, for head and neck carcinoma,
 515
 and mitomycin–vindesine, and radiotherapy, for stage III non-
 small cell lung cancer, 276
 and paclitaxel, anaphylaxis, hypersensitivity reaction profiles,
 373
 and radiotherapy, unresectable tumors of upper digestive tract,
 and vinorelbine, plus radiotherapy, for stage III-B non-small
 cell lung cancer, 404
 and WR2721, for metastatic breast cancer, 368

Claudication
 in aortic wall sarcoma, 73

Clinical trials
 amonafide for non-squamous cell carcinoma of cervix, phase II
 study, 626
 BCNU and interferon alpha, high-grade gliomas, phase II study,
 364
 bladder cancer, intravesical doxorubicin infusion, phase I-II
 study, 331
 breast cancer, metastatic, 6-thioguanine treatment, phase II
 study, 69
 carboplatin–cisplatin–etoposide, in advanced non-small cell
 lung cancer, phase II study, 51
 cervical cancer, cisplatin–5-fluorouracil and fractionation
 radiotherapy, phase I-II study, 342
 cisplatin and interferon alpha 2b, in bladder cancer, phase II
 study, 319
 cisplatin and WR2721, for metastatic breast cancer, phase II
 study, 368

cisplatin infusion with radiotherapy, for unresectable head and neck cancer, phase I study, 1

cisplatin–carboplatin–etoposide, in advanced malignancy, phase I study, 500

dose intensification with cisplatin and carboplatin plus vindesine, non-small cell lung cancer, phase II study, 393

edatrexate effects, in renal cell carcinoma, phase II study, 251

edatrexate in squamous cell cervical cancer, phase II study, 78

epirubicin with GM-CSF, in advanced cancer, phase I study, 259

estramustine–etoposide–vinorelbine, for hormone-refractory prostate cancer, phase II study, 383

fenretinide therapy, for prostate adenocarcinoma, phase II trial, 36

FLAP for metastatic gastric and gastroesophageal junction adenocarcinoma, phase II study, 242

hepatic arterial infusion of ifosfamide, in hepatocellular carcinoma, phase II study, 289

hepatic arterial infusion of ifosfamide, in inoperable hepatocellular carcinoma, 289

levamisole–interleukin-2, for advanced malignant melanoma, phase II study, 490

metastatic melanoma, comparison of single-institution phase II trial and cooperative-group phase II trial, 600

non-small cell lung cancer, stage III, cisplatin–mitomycin–vindesine, plus radiotherapy, phase II study, 276

paclitaxel, for ovarian cancer, phase II study, 230

pancreatic carcinoma, unresectable, cisplatin–5-fluorouracil, and split-course radiotherapy, phase II study, 161

roquinimex for myelodysplastic syndrome, phase II study, 189

squamous cell esophageal carcinoma, sequential chemotherapy and radiotherapy, phase II study, 151

topotecan for advanced gastric cancer, phase II study, 621

topotecan in head and neck cancer, phase II study, 298

tumor necrosis factor with interferon- α and interleukin-2, phase I study, 511

Clodronate
for prostate cancer with bone metastases, 471

CODBLAM IV chemotherapy
for large cell lymphoma, infusional vincristine and bleomycin and "high-dose" consolidation, 90

Colloid P-32
radiation dose in childhood pulmonary sarcoma, 587

Colon cancer
irinotecan hydrochloride resistance, K-ras mutation after 5-fluorouracil treatment, 527

metastatic, CI-980 (NSC 370147) treatment, 573

metastatic, low-dose vs. high-dose folinic acid, and 5-fluorouracil, 387

Conformal therapy, three-dimensional
re-irradiation of intracranial neoplasms, 358

Cyclophosphamide
See also CISCA_{II}.
and adriamycin–cisplatin treatment, for Fallopian tube carcinoma, 143

and carboplatin–etoposide, metastatic breast cancer after anthracycline therapy, 166

CEP. *See CEP*.
and cisplatin–doxorubicin treatment, for epithelial ovarian carcinoma, 522

and filgrastim vs. sequential filgrastim and molgramostim, 209

Cytology
vs. tumor markers, in malignant serous effusions, 247

Dacarbazine
ABVD. *See ABVD*.

5'-Deoxy-5-fluorouridine (5'-DFUR)
for hepatocellular carcinoma, transcatheter arterial chemoembolization, 202

Docetaxel
for breast cancer, 429

Dose intensification
cisplatin and carboplatin with vindesine, for non-small cell lung cancer, 393

epirubicin with GM-CSF, in advanced cancer, 259

filgastrim vs. sequential filgastrim and molgramostim, after carboplatin, cyclophosphamide, and etoposide, 209

Dose reduction
chemotherapeutic agents, after weight loss, 193

Doxorubicin
ABVD. *See ABVD*.
adjuvant chemotherapy for breast cancer, 219

for bladder cancer, phase I-II trial, 331

CISCA. *See CISCA_{II}*.
and cisplatin–cyclophosphamide treatment, for epithelial ovarian carcinoma, 522

and 5-fluorouracil–mitomycin-C, vs. palliation, in advanced gastric cancer, 484

infusional, with recombinant human granulocyte colony stimulating factor, 63

and radionuclide angiography, 132

Drug interactions
paclitaxel and ketoconazole, 592

Dystrophic epidermolysis bullosa
squamous cell carcinoma, radiation therapy, 55

Edatrexate
for renal cell carcinoma, 251

in squamous cell cervical cancer, 78

Ehlers–Danlos syndrome
mediastinal epithelioid hemangioendothelioma, 412

Emboli
tumor, in aortic wall sarcoma, 73

Emesis
chemotherapy-induced, intravenous granisetron vs. intravenous and oral ondansetron, 569

Encephalopathy
in carcinoid tumors, octreotide acetate treatment, 558

Endometrial carcinoma
vaginal brachytherapy, 254

Environmental smoke
squamous cell head and neck carcinoma in nonsmokers, 146

Epirubicin
with GM-CSF, in advanced cancer, 259

and mitomycin C, port-catheter implantable system, in breast cancer, 493

Epithelioid hemangioendothelioma, mediastinal
in Ehlers–Danlos syndrome, 412

Erythromycin breath test
ketoconazole and paclitaxel, drug interactions, 592

Esophageal cancer
squamous cell carcinoma, radiotherapy alternating with chemotherapy, 16

squamous cell carcinoma, sequential chemotherapy and radiotherapy, 151

surgery and multimodality therapy, 11

with upper abdominal lymphadenopathy, radiotherapy with adjuvant and concurrent chemotherapy, 580

Estramustine
and etoposide–vinorelbine, for hormone-refractory prostate cancer, 383

Estrogen
receptors, prognosis in breast cancer, 546

Etoposide
See also BEP.
 and carboplatin–cisplatin, metastatic breast cancer after anthracycline therapy, 166
 and carboplatin–cisplatin, for non-small cell lung cancer, 51
 CEP. *See CEP.*
 and cisplatin–carboplatin, in advanced malignancy, 500
 and estramustine–vinorelbine, for hormone-refractory prostate cancer, 383
 and filgrastim vs. sequential filgrastim and molgramostim, 209
 5-fluorouracil–cisplatin–leukovorin, for non-small cell lung cancer, 128
 with GM-CSF–carboplatin, for small-cell lung cancer, 24
 oral low-dose, for relapsing or refractory non-Hodgkin's lymphoma, 311

Facial nerve
 palsy, from metastasis to temporal bone, 19

Fallopian tube carcinoma
 cyclophosphamide–adriamycin–cisplatin treatment, 143

Fanconi's syndrome
 and cervical cancer, edatrexate therapy, 78

Fat necrosis
 pancreatic acinar cell carcinoma, immunohistochemistry and ultrastructure, 101

Fenretinide
 for adenocarcinoma of prostate, 36

Fibromyalgia
 after adjuvant chemotherapy for breast cancer, 3322

Filgrastim
 and adjuvant chemotherapy, for high-risk breast cancer, 169
 vs. sequential filgrastim and molgramostim, after carboplatin, cyclophosphamide, and etoposide, 209

FLAP (5-fluorouracil–leucovorin–adriamycin–cisplatin)
 for metastatic gastric and gastroesophageal junction adenocarcinoma, 242

5-Fluorouracil (5-FU)
 and cisplatin, continuous infusion in bladder cancer, 327
 and cisplatin, and fractionation radiotherapy, for cervical cancer, 342
 and cisplatin, and split-course radiotherapy, pancreatic carcinoma, 161
 for colon cancer, irinotecan hydrochloride resistance, *K-ras* mutation, 527
 and doxorubicin–mitomycin-C, vs. palliation, for advanced gastric cancer, 484
 and etoposide–cisplatin–leukovorin, for non-small cell lung cancer, 128
 in FLAP. *See FLAP.*
 and leucovorin–interferon- α -2b–cisplatin, for pancreatic adenocarcinoma, 81
 and low-dose vs. high-dose folinic acid, for metastatic colorectal cancer, 387
 and mitomycin C–cisplatin, for head and neck carcinoma, 515
 radiosensitization, hypofractionated radiotherapy, for far-advanced breast cancer, 562

Folinic acid
 low-dose vs. high-dose, and 5-fluorouracil, for metastatic colorectal cancer, 387

Fractionation. *See Radiotherapy.*

Functional Living Index-Cancer
 health status in bone metastases, 424

Gallium nitrate
 and hydroxyurea, for refractory non-Hodgkin's lymphoma, 173

Gastric carcinoma. *See Stomach.*

Gastroesophageal junction adenocarcinoma
 metastatic, FLAP effects, 242

Gene expression
 multidrug-resistant, in small-cell lung cancer, 398

Germ cell tumors
 nonseminomatous, BEP and CISCA_{II}/VB_{IV} regimens, 184

Glioma, malignant
 intracarotid cisplatin, and concurrent radiation, 138

Glossitis, herpetic geometric
 in child with myelogenous leukemia, 567

Gonadal function
 after ABVD therapy for Hodgkin's disease, 354

Grafts
 radiating jejunal interposition, in head and neck cancer, 609

Granisetron
 intravenous, vs. intravenous and oral ondansetron, for chemotherapy-associated nausea and vomiting, 569

Granulocyte–colony stimulating factor (G-CSF)
 combined with infusional chemotherapy, 63
 recombinant human, and high-dose CEP, 266

Granulocyte–macrophage colony-stimulating factor (GM-CSF)
 and epirubicin, in advanced cancer, 259
 with etoposide and carboplatin, for small-cell lung cancer, 24

Head and neck cancer
 advanced and/or recurrent, mitomycin C–cisplatin–5-fluorouracil, 515
 chemotherapy role, 449
 preoperative simultaneous chemoradiotherapy, 97
 radiating jejunal interposition grafts, 609
 radiotherapy-induced mucositis, prophylactic immunoglobulin, 407
 recurrent, topotecan effects, 298
 squamous, in nonsmokers, 146
 unresectable, radiotherapy with cisplatin infusion, 1

Health status
 in bone metastases, 424

Heart
 transplantation, extramedullary plasmacytoma, 467

Hemangiopericytoma, mediastinal epithelioid
 in Ehlers–Danlos syndrome, 412

Hematology
 epirubicin with GM-CSF, in advanced cancer, phase I study, 259
 roquinimex for myelodysplastic syndrome, 189

Hepatocellular carcinoma
 inoperable, hepatic arterial infusion of ifosfamide, 289
 presenting as pancreatic head mass, 509
 transcatheter arterial chemoembolization, 5'-DFUR as adjuvant chemotherapy, 202

Herpes
 geometric glossitis, in child with myelogenous leukemia, 567

High dose rate
 CEP, with rhG-CSF, 266
 vaginal brachytherapy, in endometrial carcinoma, 254

Histiocytoma, fibrous
 and aortic wall sarcoma, 73

Histomorphometry
 clodronate for prostate cancer with bone metastases, 471

Historical perspective
 breast cancer, systemic or local disease, 536

Hodgkin's disease
 gonadal function after ABVD therapy, 354

Hormonal therapy
 megestrol acetate for prostate cancer, 308
 for metastatic prostate cancer, 40
 small cell anaplastic carcinoma of prostate, 376

Hydroxyurea
 and gallium nitrate, for refractory non-Hodgkin's lymphoma, 173

Hypersensitivity reactions
 anaphylaxis from cisplatin/paclitaxel, 373
 docetaxel treatment, for breast cancer, 429

Hyperthermia
 for eccrine spiradenoma, 552
 for prostate cancer, 111

Hypocalcemia
 in miliary osteosarcomatosis, 505

Ifosfamide
 and bleomycin, addition to cisplatin-ifosfamide, for cervical carcinoma, 315
 hepatic arterial infusion, in hepatocellular carcinoma, 289
 infusional, with recombinant human granulocyte colony stimulating factor, 63
 outpatient treatment for bladder cancer, 519

Immunoglobulin
 prophylactic, and radiotherapy-induced oral mucositis, 407

Immunohistochemistry
 pancreatic acinar cell carcinoma, 101

Immunotherapy
 levamisole and interleukin-2, in malignant melanoma, 490
 for prostate cancer, 111

Infections
 herpetic geometric glossitis, in child with myelogenous leukemia, 567
Strongyloides stercoralis, in small noncleaved cell lymphoma, 215

Interferon alpha
 and BCNU, high-grade gliomas, 364
 with tumor necrosis factor, 511

Interferon alpha 2b
 and cisplatin, in bladder cancer, phase II study, 319
 and leucovorin-5-FU-cisplatin, for pancreatic adenocarcinoma, 81

Interleukin-2
 and levamisole, for advanced malignant melanoma, 490
 with tumor necrosis factor, 511

Irinotecan hydrochloride (CPT-11)
 resistance, *K-ras* mutation in colon cancer, after 5-fluorouracil treatment, 527

Irradiation
 and blood-CSF barrier permeability of chemotherapeutic agents, 263
 brain tumors, with three-dimensional conformal therapy, 358
 breast cancer, cellulitis as complication, 338

Ischemia
 peripheral, in aortic wall sarcoma, 73

Ischial tuberosities
 in prostate cancer, 479

Jaundice, obstructive
 hepatocellular carcinoma, presenting as pancreatic head mass, 509

Jejunal interposition
 radiating grafts, in head and neck cancer, 609

Ketoconazole
 and paclitaxel, drug interactions, 592

Kidney
 acute renal failure with suramin treatment, 433

K-ras mutation
 after 5-fluorouracil for colon cancer, irinotecan hydrochloride resistance, 527

Larynx
 T2NO squamous cell carcinoma of true vocal cords, neck failure, 154

Letter to the Editor
 Taxol-Induced Cellulitis after Extravasation: A Rarely Reported Event, 540

Leucovorin
 in FLAP. *See* FLAP.
 and 5-fluorouracil-cisplatin-etoposide, for non-small cell lung cancer, 128
 and 5-fluorouracil-interferon- α -2b-cisplatin, for pancreatic adenocarcinoma, 81

Leukemia
 heterogeneity, after sarcoma treatment, 585
 myelogenous, herpetic geometric glossitis, in child, 567

Levamisole
 and interleukin-2, for advanced malignant melanoma, 490

Liver
 arterial infusion of ifosfamide, in inoperable hepatocellular carcinoma, 289
 arterial perfusion scintigraphy, angiotensin II effects on arteriovenous shunting, 237
 hepatocellular carcinoma, presenting as pancreatic head mass, 509
 hepatocellular carcinoma, transcatheter arterial chemoembolization, 5'-DFUR as adjuvant chemotherapy, 202

Lung cancer
 brain metastasis, combination chemotherapy, 303
 carcinoid tumors, prognostic factors, 285
 colloid P-32, and radiation dose in childhood pulmonary sarcoma, 587
 non-small cell, carboplatin-cisplatin-etoposide combination chemotherapy, 51
 non-small cell, cisplatin and carboplatin therapy, 31
 non-small cell, cisplatin-5-FU-leucovorin-etoposide, 128
 non-small cell, dose intensification with cisplatin and carboplatin plus vindesine, 393
 non-small cell, hyperfractionated radiotherapy and concurrent chemotherapy, 435
 non-small cell, mitomycin toxicity, 282
 non-small cell, postoperative radiation therapy, 441
 non-small cell, radiotherapy for intrathoracic recurrence, 46
 non-small cell, stage III, cisplatin-mitomycin-vindesine, and radiotherapy, 276
 non-small cell, stage III-B, cisplatin-vinorelbine plus radiotherapy, 404
 small-cell, with brain metastases, 125
 small-cell, in elderly patients, teniposide effects, 477
 small-cell, etoposide-carboplatin-GM-CSF, phase I trial, 24
 small-cell, multidrug-resistant gene expression, 398

Lymphadenopathy
 upper abdominal, in esophageal carcinoma, radiotherapy with adjuvant and concurrent chemotherapy, 580

Lymphocytosis
 T-cell, in invasive thymoma, tumor lysis syndrome, 86

Lymphoma
 large cell, COBBLAM IV chemotherapy, infusional vincristine and bleomycin and "high-dose" consolidation, 90
 non-Hodgkin's, gallium nitrate and hydroxyurea, 173
 non-Hodgkin's, of maxillary sinus, 272
 non-Hodgkin's, POCA and VEC-POB chemotherapy, 179
 non-Hodgkin's, relapsing or refractory, oral low-dose etoposide effects, 311
 non-Hodgkin's, testicular, 59
 small noncleaved cell, *Strongyloides stercoralis* infection, 215

Mammography
 breast cancer, systemic or local disease, 536

Mastectomy
 breast cancer, bilateral vs. unilateral disease, 541

Maxillary sinus
non-Hodgkin's lymphoma, 272

Medulloblastoma
recurrent, paclitaxel with fractionated stereotactic radiotherapy, 233

Megesterol acetate
for hormone-refractory prostate cancer, 308

Melanoma, malignant
levamisole and interleukin-2, 490

Melanoma, metastatic
comparison of single-institution phase II trial and cooperative-group phase II trial, 600

Mesna
with ifosfamide, outpatient treatment for bladder cancer, 519

Metastases
bone, health status, 424
bone, in prostate cancer, clodronate effects, 471
brain, from breast and lung adenocarcinoma, 303
brain, hyperfractionated re-irradiation, 158
brain, in small-cell lung cancer, 125
breast cancer, carboplatin-cyclophosphamide-eposide, after anthracycline therapy, 166
breast cancer, cisplatin and WR2721, 368
breast cancer, docetaxel treatment, 429
breast cancer, 6-thioguanine treatment, 69
colorectal cancer, low-dose vs. high-dose folinic acid, and 5-fluorouracil, 387
colorectal carcinoma, CI-980 (NSC 370147) treatment, 573
ecrine spiradenoma, 552
gastric and gastroesophageal junction adenocarcinoma, FLAP effects, 242
hepatocellular carcinoma presenting as pancreatic head mass, 509
melanoma, comparison of single-institution phase II trial and cooperative-group phase II trial, 600
placental, from maternal neuroectodermal tumor, 628
prostate, transitional cell carcinoma, mitoxantrone treatment, 381
prostate cancer, age factors and serum testosterone, 605
renal cell cancer, spontaneous regression, 416
spinal cord, secondary syringomyelia, 577
to temporal bone, facial nerve palsy, 19

Methotrexate
alternating with radiotherapy, for esophageal cancer, 16

Mitomycin
and cisplatin-vindesine, and radiotherapy, for stage III non-small cell lung cancer, 276
lung toxicity, 282

Mitomycin C
and cisplatin-5-fluorouracil, for head and neck carcinoma, 515
and epirubicin, port-catheter implantable system, in breast cancer, 493
and 5-fluorouracil-doxorubicin, vs. palliation, in advanced gastric cancer, 484

Mitoxantrone
for prostate cancer, 381

Molgramostim
and filgrastim, after carboplatin, cyclophosphamide, and etoposide, 209

Mucositis
radiotherapy-induced, prophylactic immunoglobulin, 407

Multidrug resistant gene
in small-cell lung cancer, 398

Myelodysplastic syndrome
and leukemia heterogeneity, after sarcoma treatment, 585
roquinimex therapy, 189

Myeloma, multiple
autologous stem cell and allogeneic bone marrow transplantation, 462
and extramedullary plasmacytoma, after cardiac transplantation, 467

Nasopharyngeal cancer
radiotherapy and concurrent chemotherapy, 6

Neck
failure, in T2N0 squamous cell carcinoma of true vocal cords, 154

Neck cancer. *See* Head and neck cancer.

Neuroectodermal tumor
maternal, and placental metastasis, 628

Neurotoxicity
CI-980 (NSC 370147) treatment, for metastatic colorectal carcinoma, 573

Non-Hodgkin's lymphoma
gallium nitrate and hydroxyurea, 173
of maxillary sinus, 272
POCA and VEC-POB chemotherapy, 179
relapsing or refractory, oral low-dose etoposide effects, 311
testicular, 59

NSC 370147
for colorectal carcinoma, 573

Octreotide acetate
for encephalopathy in carcinoid tumors, 558

Ondansetron
intravenous and oral, vs. intravenous granisetron, for chemotherapy-induced emesis, 569

Oral cavity and oropharynx. *See* Head and neck cancer.

Osteosarcomatosis, miliary
with associated hypocalcemia, 505

Outpatient treatment
ifosfamide for bladder cancer, 519

Ovarian cancer
epithelial, cisplatin-doxorubicin-cyclophosphamide treatment, 522
paclitaxel as salvage therapy, 230

Paclitaxel
and cisplatin, anaphylaxis, hypersensitivity reaction profiles, 373
with fractionated stereotactic radiotherapy, for recurrent medulloblastoma, 233
and ketoconazole, drug interactions, 592
for ovarian cancer, phase II study, 230

Palliation
vs. 5-fluorouracil-doxorubicin-mitomycin-C, in advanced gastric cancer, 484
Wallstent catheter for vena cava syndromes, superior and inferior, 293

Pancreatic cancer
hepatocellular carcinoma presenting as, 509

Pancreatic carcinoma
acinar cell, immunohistochemistry and ultrastructure, 101
5-fluorouracil-leucovorin-interferon- α -2b-cisplatin treatment, 81
unresectable, cisplatin-5-fluorouracil, and split-course radiotherapy, phase II study, 161

Peplomycin
alternating with radiotherapy, for esophageal cancer, 16

Pharmacokinetics
chemotherapeutic agents, dose reduction after weight loss, 193
cisplatin infusion with radiotherapy, for unresectable head and neck cancer, 1

doxorubicin, intravesical, for bladder cancer, 331

Piroxantrone
in squamous cell carcinoma of cervix, 84

Placenta
metastasis, from maternal neuroectodermal tumor, 628

Plasmacytoma
extramedullary, after cardiac transplantation, 467

POCA
and VEC-POB chemotherapy, for non-Hodgkin's lymphoma, 179

Port-catheter implantable system
induction intraarterial chemotherapy for breast cancer, 493

Progesterone
receptors, prognosis in breast cancer, 546

Prophylaxis
immunoglobulin, and radiotherapy-induced oral mucositis, 407

Prostate cancer
adenocarcinoma, diagnosis and management, 111
bone metastasis, clodronate effects, 471
fenretinide therapy, phase II trial, 36
hormone-refractory, estramustine–etoposide–vinorelbine effects, 383
hormone-refractory, megestrol acetate effects, 308
metastatic, age factors and serum testosterone, 605
metastatic, therapeutic options, 40
metastatic transitional cell carcinoma, mitoxantrone treatment, 381
radiation therapy after prostatectomy, 120
retrograde urethrogram, ischial tuberosities, 479
small cell anaplastic carcinoma, therapeutic strategy, 376
suramin treatment, acute renal failure, 433

Purging
soybean agglutinin, and autologous stem cell transplantation, in breast cancer, 419

Quality of life
brain metastases, hyperfractionated re-irradiation, 158
health status in bone metastases, 424
recurrent head and neck cancer, topotecan effects, 298

Questionnaire
doxorubicin treatment, and radionuclide angiography, 132

Radiography
prostate cancer, retrograde urethrogram, ischial tuberosities, 479

Radionuclide angiography
and doxorubicin-based chemotherapy, 132

Radiotherapy
with adjuvant and concurrent chemotherapy, esophageal carcinoma with upper abdominal lymphadenopathy, 580
adjuvant, after prostatectomy, 120
alternating with chemotherapy, for esophageal cancer, 16
brain metastases, hyperfractionated re-irradiation, 158
breast cancer, bilateral vs. unilateral disease, 541
and carboplatin infusion, in cervical carcinoma, 613
and chemotherapy, for cancer of oral cavity and oropharynx, 97
and chemotherapy, sequential, for squamous cell esophageal carcinoma, 151
chemotherapy and surgery, for esophageal cancer, 11
in childhood pulmonary sarcoma, use of colloidal P-32, 587
with cisplatin infusion, unresectable tumors of upper digestive tract, 1
and cisplatin–mitomycin–vindesine, for stage III non-small cell lung cancer, 276
and cisplatin–vinorelbine, for non-small cell lung cancer, 404
and concurrent chemotherapy, for nasopharyngeal cancer, 6
eccrine spiradenoma, 552
fractionated, and cisplatin–5-fluorouracil, for cervical cancer, 342

fractionated, 5-fluorouracil radiosensitization, for far-advanced breast cancer, 562

fractionated stereotactic, with cisplatin, for malignant astrocytoma, 226

fractionated stereotactic, paclitaxel for recurrent medulloblastoma, 233

hyperfractionated, and concurrent chemotherapy, for non-small cell lung cancer, 435

and intracarotid cisplatin, for malignant gliomas, 138
for intrathoracic recurrence of non-small cell lung cancer, 46
jejunal interposition grafts, in head and neck cancer, 609
mediastinal epithelioid hemangioendothelioma, in Ehlers–Danlos syndrome, 412
for metastatic prostate cancer, 40
mucositis induced by, prophylactic immunoglobulin, 407
non-Hodgkin's lymphoma, of maxillary sinus, 272
postoperative, in non-small cell lung cancer, 441
postorchiectomy, stage II seminoma, 196
for prostate cancer, 111
re-irradiation of intracranial neoplasms, with three-dimensional conformal therapy, 358

split-course, concomitant cisplatin–5-FU, unresectable pancreatic carcinoma, 161

for squamous cell carcinoma in dystrophic epidermolysis bullosa, 55
for syringomyelia, spinal cord metastasis, 577
vocal cord T2N0 squamous cell carcinoma, neck failure, 154

Receptors
steroid, prognosis in breast cancer, 546

Recurrence
bladder cancer, transitional cell, 5-fluorouracil–cisplatin infusion, 327
cervical cancer, bleomycin–ifosfamide addition to cisplatin–ifosfamide, 315
head and neck cancer, mitomycin C–cisplatin–5-fluorouracil, 515
head and neck cancer, topotecan effects, 298
medulloblastoma, paclitaxel with fractionated stereotactic radiotherapy, 233
non-small cell lung cancer, radiotherapy, 46
postorchiectomy radiotherapy, stage II seminoma, 196
small cell anaplastic carcinoma of prostate, 376

Regression, spontaneous
metastatic renal cell cancer, 416

Renal cell cancer
edatrexate effects, 251
metastatic, spontaneous regression, 416

Rheumatism
after adjuvant therapy for breast cancer, 322

Roquinimex
for myelodysplastic syndrome, 189

RTOG 83-11 and RTOG 91-06
and hyperfractionated radiotherapy, for non-small cell lung cancer, 435

Salvage therapy
carboplatin–cyclophosphamide–etoposide, for breast cancer, 166
paclitaxel, for ovarian cancer, 230

Sarcomas
aortic wall, with tumor emboli and peripheral ischemia, 73
osteogenic, miliary, with associated hypocalcemia, 505
pulmonary, colloidal P-32 to reduce radiation dose, 587
treatment, and leukemia heterogeneity, 585

Scintigraphy
hepatic arterial perfusion, angiotensin II effects on arteriovenous shunting, 237

Screening
 breast cancer, systemic or local disease, 536
 for prostate cancer, 111

Seminoma
 stage II, postorchietomy radiotherapy, 196

Serous effusions
 malignant, tumor markers, 247

Smoking
 squamous cell head and neck carcinoma in nonsmokers, 146

Somatostatin
 analogue octreotide acetate, for encephalopathy in carcinoid tumors, 558

Soybean agglutinin purging
 and autologous stem cell transplantation, in breast cancer, 419

Spinal cord
 metastasis, secondary syringomyelia, 577

Spiradenoma
 malignant eccrine, 552

Squamous cell carcinoma
 cervical cancer, carboplatin infusion during radiotherapy, 613
 cervical cancer, cisplatin-5-fluorouracil and fractionation radiotherapy, phase I-II study, 342
 cervical cancer, edatrexate therapy, 78
 cervical cancer, piroxantrone treatment, 84
 in dystrophic epidermolysis bullosa, radiation therapy, 55
 esophageal, sequential chemotherapy and radiotherapy, 151
 of esophagus, radiotherapy alternating with chemotherapy, 16
 head and neck, in nonsmokers, 146
 head and neck cancer, mitomycin C-cisplatin-5-fluorouracil, 515
 T2N0, of true vocal cords, neck failure, 154

Stem cell transplantation, autologous
 for multiple myeloma, 462
 and soybean agglutinin purging, in breast cancer, 419

Stereotactic techniques
 fractionated radiotherapy, and cisplatin, for malignant astrocytoma, 226
 fractionated radiotherapy, paclitaxel for recurrent medulloblastoma, 233

Steroids
 receptors, prognosis in breast cancer, 546
 for syringomyelia, spinal cord metastasis, 577

Stomach
 gastric and gastroesophageal junction adenocarcinoma, FLAP effects, 242
 gastric cancer, 5-fluorouracil-doxorubicin-mitomycin-C, vs. palliation, 484
 gastric cancer, topotecan treatment, 621
 gastric carcinoma, CEA, CA 19-9, and CA-50 in monitoring, 348

Strongyloides stercoralis infection
 in small noncleaved cell lymphoma, 215

Suramin
 for prostate cancer, acute renal failure, 433

Surgical treatment
 breast cancer, cellulitis as complication, 338
 and multimodality therapy, for esophageal cancer, 11
 postoperative radiotherapy, in non-small cell lung cancer, 441
 preoperative chemoradiotherapy, for cancer of oral cavity and oropharynx, 97
 for prostate cancer, 111
 for prostate cancer, adjuvant radiotherapy, 120

Survival rates
 brain metastases, hyperfractionated re-irradiation, 158
 breast cancer, bilateral vs. unilateral disease, 541
 carcinoid tumors of lung, prognostic factors, 285
 doxorubicin as adjuvant chemotherapy, in breast cancer, 219
 head and neck cancer, chemotherapy role, 449

metastatic melanoma, comparison of single-institution phase II trial and cooperative-group phase II trial, 600
 multidrug-resistant gene expression, in small-cell lung cancer, 398
 multiple myeloma, autologous stem cell and allogeneic bone marrow transplantation, 462
 non-Hodgkin's lymphoma, of maxillary sinus, 272
 non-Hodgkin's lymphoma, POCA and VEC-POB chemotherapy, 179
 postoperative radiotherapy, in non-small cell lung cancer, 441
 postorchietomy radiotherapy, stage II seminoma, 196
 prostate cancer, adjuvant radiotherapy after prostatectomy, 120
 radiotherapy for intrathoracic recurrence of non-small cell lung cancer, 46
 recurrent head and neck cancer, topotecan effects, 298
 small cell anaplastic carcinoma of prostate, 376
 small-cell lung cancer with brain metastases, 125
 testicular non-Hodgkin's lymphoma, 59

Sweat glands
 eccrine spiradenoma, 552

Syringomyelia
 secondary, spinal cord metastasis, 577

T-cell lymphocytosis
 in invasive thymoma, tumor lysis syndrome, 86

Temporal bone
 metastasis, facial nerve palsy, 19

Teniposide
 for small-cell lung cancer, in elderly patients, 477

Testes
 non-Hodgkin's lymphoma, 59
 postorchietomy radiotherapy, stage II seminoma, 196

Testosterone
 and age factors in metastatic prostate cancer, 605

6-Thioguanine
 for metastatic breast cancer, 69

Thymoma
 with peripheral blood T-cell lymphocytosis, tumor lysis syndrome, 86

Topotecan
 for advanced gastric cancer, phase II study, 621
 in head and neck cancer, 298

Toxicity
 carboplatin infusion during radiotherapy, in cervical cancer, 613
 cardiac, doxorubicin as adjuvant chemotherapy, in breast cancer, 219
 chemotherapy alternating with radiotherapy, for esophageal cancer, 16
 chemotherapy and concurrent radiotherapy, for nasopharyngeal cancer, 6
 cisplatin, intracarotid, and concurrent radiation, for malignant glioma, 138
 cisplatin and interferon alpha 2b, in bladder cancer, 319
 cisplatin and WR2721, in breast cancer, 368
 CODBLAM IV-vincristine-bleomycin chemotherapy, for large cell lymphoma, 90
 doxorubicin, and radionuclide angiography, 132
 doxorubicin, intravesical, for bladder cancer, 331
 edatrexate effects, in renal cell carcinoma, 251
 epirubicin with GM-CSF, in advanced cancer, phase I study, 259
 filgrastim and adjuvant chemotherapy, for high-risk breast cancer, 169
 filgrastim vs. sequential filgrastim and molgramostim, after carboplatin, cyclophosphamide, and etoposide, 209
 gallium nitrate and hydroxyurea, in non-Hodgkin's lymphoma, 173
 G-CSF combined with infusional chemotherapy, 63

in head and neck cancer, chemotherapy role, 449
 mitomycin, in lung, 282
 paclitaxel, in ovarian cancer, 230
 postorchietomy radiotherapy, stage II seminoma, 196
 rhG-CSF with high-dose CEP, 266
 transcatheter arterial embolization, 5'-DFUR for hepatocellular carcinoma, 202

Transplantation
 autologous blood stem cell, and allogeneic bone marrow, for multiple myeloma, 462
 cardiac, extramedullary plasmacytoma, 467

Tumor lysis syndrome
 in thymoma with peripheral blood T-cell lymphocytosis, 86

Tumor markers
 diagnosis of malignant serous effusions, 247
 in monitoring gastric carcinoma, 348

Tumor necrosis factor
 and interferon- α and interleukin-2, 511

Tumors
 advanced, epirubicin with GM-CSF, 259
 advanced malignancy, etoposide-cisplatin-carboplatin, 500
 unresectable, of head and neck, radiotherapy with cisplatin infusion, 1
 vena cava syndromes, superior and inferior, Wallstent catheter placement, 293

Ultrastructure
 pancreatic acinar cell carcinoma, 101

Urethrography, retrograde
 in prostate cancer, 479

Vagina
 brachytherapy, in endometrial carcinoma, 254

VB_{IV} (vinblastine-bleomycin)
 and BEP, germ cell tumors, 184

VEC-POB
 and POCA chemotherapy, for non-Hodgkin's lymphoma, 179

Vena cava syndromes
 superior and inferior, Wallstent catheter placement, 293

Vinblastine
 ABVD. *See* ABVD.
See also VB_{IV}.

Vincristine
 and CODBLAM IV chemotherapy, for large cell lymphoma, 90

Vindesine
 and cisplatin-carboplatin, for non-small cell lung cancer, 393
 and cisplatin-mitomycin, and radiotherapy, for stage III non-small cell lung cancer, 276

Vinorelbine
 and cisplatin, plus radiotherapy, for stage III-B non-small cell lung cancer, 404
 and estramustine-etoposide, for hormone-refractory prostate cancer, 383

VM26 (teniposide)
 for small-cell lung cancer, in elderly patients, 477

Vocal cords
 T2N0 squamous cell carcinoma, neck failure, 154

Wallstent catheter
 for vena cava syndromes, superior and inferior, 293

Weight loss
 dose reduction of chemotherapeutic agents, 193

WR2721
 and cisplatin, for metastatic breast cancer, phase II study, 368

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970; Section 3685, Title 39 United States Code) Date of Filing—October 1, 1997. Title of Publication—American Journal of Clinical Oncology; Frequency of Issue—Bimonthly; Annual Subscription Price—\$183.00; Location of Known Office of Publication—Lippincott-Raven Publishers, 12107 Insurance Way, Hagerstown, MD 21740; Location of the Headquarters or General Business Offices of the Publisher—227 East Washington Square, Philadelphia, PA 19106; Publisher—Lippincott-Raven Publishers, 227 E. Washington Square, Philadelphia, PA 19106; Editor—Luther W. Brady, M.D., Department of Radiation Oncology, Allegheny University of the Health Sciences, MCP/Hahnemann University School of Medicine (MS 200), Broad and Vine Streets, Philadelphia, PA 19102; Managing Editor—Elisa Schulz, Lippincott-Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Owner—Lippincott-Raven Publishers, a wholly owned subsidiary of Wolters-Kluwer, US Corp., 227 E. Washington Square, Philadelphia, PA 19106, 36th Floor, 1185 Avenue of the Americas, New York City, NY 10036; Known Bondholders, Mortgagors, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—none. A. Total no. copies printed (*net press run*), average 2,183, actual 2,100; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 1,266, actual 1,266; C. Total paid circulation, average 1,266, actual 1,266; D. Free distribution by mail, carrier or other means. Samples, complimentary, and other free copies, average 259, actual 265; E. Total distribution (*sum of C and D*), average 1,525, actual 1,531; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 658, actual 569; 2. Returns from news agents, none; G. Total (*sum of E & F—should equal net press runs shown in A*), average 2,183, actual 2,100. I certify that the statements made by me above are correct and complete. Beverly V. Dietrich, *Circulation Director*.

